Somatostatin-dopamine chimeric analogs

ABSTRACT

The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.

BACKGROUND OF THE INVENTION

This application is a continuation-in-part of copending U.S. applicationSer. No. 10/553,014 filed on Oct. 11, 2005, which is a United Statesnational stage filing under 35 U.S.C. §371 of international (PCT)application No. PCT/US2004/10891, Apr. 8, 2004, and designating the US,which claims priority to U.S. provisional application 60/462,374 filedApr. 11, 2003.

The present invention is drawn to somatostatin-dopamine chimeric analogsand methods relating to their therapeutic use.

Dopamine is a catecholamine neurotransmitter that has been implicated inthe pathogenesis of both Parkinson disease and schizophrenia. Dopamineand related molecules have been shown to inhibit the growth of severaltypes of malignant tumors in mice, and this activity has been variouslyattributed to inhibition of tumor-cell proliferation, stimulation oftumor immunity or as well as effects on melanin metabolism in malignantmelanomas. Recent studies demonstrated the presence of D2 dopaminereceptors on endothelial cells. Dopamine has recently been reported tostrongly and selectively inhibit at non-toxic levels the vascularpermeabilizing and angiogenic activities of VPF/VEGF.

Somatostatin (SS), a tetradecapeptide has been shown to have potentinhibitory effects on various secretory processes in tissues such aspituitary, pancreas and gastrointestinal tract. SS also acts as aneuromodulator in the central nervous system. These biological effectsof SS, all inhibitory in nature, are elicited through a series of Gprotein coupled receptors, of which five different subtypes have beencharacterized (SSTR-1-SSTR-5). These five subtypes have similaraffinities for endogenous SS ligands, but have differing distributionsin various tissues. Somatostatin binds to the five distinct receptor(SSTR) subtypes with relatively high and equal affinity for eachsubtype.

There is evidence that SS regulates cell proliferation by arresting cellgrowth via SSTR-1, -2, -3, -4, and -5 subtypes, and/or by inducingapoptosis via SSTR-3 subtype. SS and various analogues have been shownto inhibit normal and neoplastic cell proliferation in vitro and in vivovia specific SS receptors (SSTR's) and possibly different postreceptoractions. In addition, there is evidence that distinct SSTR subtypes areexpressed in normal and neoplastic human tissues, conferring differenttissue affinities for various SS analogues and variable clinicalresponse to their therapeutic effects.

Binding to different types of somatostatin receptor subtypes isassociated with the treatment of various conditions and/or diseases. Forexample, the inhibition of growth hormone has been attributed to thesomatostatin type-2 receptor (“SSTR-2”), while the inhibition of insulinhas been attributed to the somatostatin type-5 receptor (“SSTR-5”).Activation of types 2 and 5 have been associated with growth hormonesuppression and more particularly growth hormone secreting adenomas(acromegaly) and thyroid stimulating hormone (TSH) secreting adenomas.Activation of type 5 but not type 2 receptor has been associated withtreating prolactin secreting adenomas. Other indications associated withactivation of the somatostatin receptor subtypes include inhibition ofinsulin and/or glucagon for treating diabetes mellitus, angiopathy,proliferative retinopathy, dawn phenomenon, and nephropathy; inhibitionof gastric acid secretion for treating peptic ulcers, enterocutaneousand pancreaticocutaneous fistula, irritable bowel syndrome, Dumpingsyndrome, watery diarrhea syndrome, AIDS related diarrhea,chemotherapy-induced diarrhea, acute or chronic pancreatitis andgastrointestinal hormone secreting tumors; treatment of cancer such ashepatoma; inhibition of angiogenesis; treatment of inflammatorydisorders such as arthritis; retinopathy; chronic allograft rejection;angioplasty; preventing graft vessel and gastrointestinal bleeding.Preferably, a somatostatin analog is selective for the specificsomatostatin receptor subtype or subtypes responsible for the desiredbiological response to reducing interaction with other receptor subtypeswhich could lead to undesirable side effects or loss of efficacy.

Somatostatin and its receptors (SSTR-1 to SSTR-5) are expressed innormal human parafollicular C cells and medullary thyroid carcinoma(MTC). MTC is a tumor originating from thyroid parafollicular C cellsthat produces calcitonin (CT), somatostatin, and several other peptides.It was recently demonstrated that SS and SSTR's are expressed in humanMTC, and SS and SS analogues were shown to induce a decrease in plasmaCT levels and provide symptomatic improvement in MTC patients. Anotherrecent study has shown that SS and SS analogs, in particular, SSTR-1 andSSTR-2, can inhibit the proliferation of tumor cells, suggesting thatspecific SSTR subtypes can function in MTC cell growth regulation. Thedevelopment and characterization of SSTR subtype analogues thatselectively effect MTC cell growth is useful for clinical andtherapeutic applications.

SUMMARY OF THE INVENTION

The present invention is based on our discovery of somatostatin-dopaminechimeric analogs, comprising compounds that retain both somatostatin anddopamine activity. The chimeric analogs of the invention are consideredto be useful, e.g., in vitro, for use as research tools, diagnosticassays, etc., or in vivo, for use as diagnostic or therapeutic agents.Preferred chimeric analogs of the invention display enhanced activitywhen compared to native somatostatin and dopamine, either alone or incombination.

Accordingly, in a first aspect, the invention features a chimeric analogcomprising (1) at least one moiety which binds to one or moresomatostatin receptor(s) and (2) at least one moiety which binds to oneor more dopamine receptor(s), or a pharmaceutically acceptable saltthereof.

In a first embodiment of the first aspect, the chimeric analog comprisesformula (I),

wherein:

-   -   X is H, Cl, Br, I, F, —CN, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀        alkenyl, C₂₋₁₀ alkynyl, substituted C₁₋₁₀ alkyl, substituted        C₁₋₁₀ heteroalkyl, substituted C₂₋₁₀ alkenyl, or substituted        C₂₋₁₀ alkynyl;    -   R1 is H, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀        alkynyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl,        substituted C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkynyl, or —CN;    -   R2 and R3, each is, independently, H or absent, provided that        when R2 and R3 are absent a double bond is present between the        carbon atoms to which they are attached;    -   R4 is H, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀        alkynyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl,        substituted C₂₋₁₀ alkenyl, or substituted C₂₋₁₀ alkynyl;    -   Y is —O—, —C(O)—, —S—, —S—(CH₂)_(s)—C(O)—, —S(O)—, —S(O)₂—,        —SC(O)—, —OC(O)—, N(R5)—C(O)—, or —N(R6)—;    -   L is —(CH₂)_(p)—C(O)—, when Y is —S—, —S(O)—, —S(O)₂—, —O— or        —N(R6)—; or L is —C(O)—(CR7R8)_(q)—C(O)—, when Y is —N(R6)—,        —O—, or —S—; or L is (amino acid)_(t), when Y is —C(O)—, SC(O)—,        —OC(O)—, —S—(CH₂)_(s)—C(O)—, or —N(R5)—C(O)—;    -   W is —CR9,R10-;    -   R5 and R6 each is, independently, H, C₁₋₁₀ alkyl, substituted        C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl,        C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,        substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted        alkylaryl;

R7, R8, R9, and R10 each is, independently, H, F, C1, Br, I, C₁₋₁₀alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; orR7 and R8 can, optionally, join together to form a ring system; or R9and R10 can, optionally, join together to form a ring system;

-   -   i is 1-10, provided that when i is 1, then R1 is not H, C₁₋₄        alkyl, allyl, alkenyl or —CN, R4 is not H or —CH₃, R5, R6, R7        and R8 each is, independently, not H or C₁₋₅ alkyl, L is not        -(Doc)_(t)-, X is not H, Cl, Br, I, F, —CN, or C₁₋₅ alkyl, or R9        and R10 each is, independently, not H;    -   m is 0 or 1;    -   n is 0-10;    -   p is 1-10;    -   q is 1-5;    -   s is 1-10;    -   t is 1-10;    -   Z is a ligand of at least one somatostatin receptor;    -   or a pharmaceutically acceptable salt thereof; and    -   wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group, carboxylic acid group, or hydroxyl        group of Z.

In a second aspect of the first embodiment, the chimeric analogcomprises formula (II),

wherein:

-   -   X is H, Cl, Br, I, F, —CN, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀        alkenyl, C₂₋₁₀ alkynyl, substituted C₁₋₁₀ alkyl, substituted        C₁₋₁₀ heteroalkyl, substituted C₂₋₁₀ alkenyl, or substituted        C₂₋₁₀ alkynyl;    -   R1 is H, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀        alkynyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl,        substituted C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkynyl, or —CN;    -   R2 and R3, each is, independently, H or absent, provided that        when R2 and R3 are absent a double bond is present between the        carbon atoms to which they are attached;

R4 is H, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl, substitutedC₂₋₁₀ alkenyl, or substituted C₂₋₁₀ alkynyl;

-   -   R5 is H, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀        alkynyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl,        substituted C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkynyl, or a group        of the formula of —(CH₂)_(r)N(R11,R12);

Y is —O—, —C(O)—, —S—, —SC(O)—, —OC(O)—, —N(R6)—C(O)—, —N(R7)—, or—N(R8)—(CH₂)_(s)—C(O)—;

-   -   L is —(CH₂)_(p)—C(O)—, when Y is —S—, —O— or —N(R7)—; or L is        —C(O)—(CR9R10)_(q)—C(O)—, when Y is —N(R7)—, —O—, or —S—; or L        is (amino acid)_(t), when Y is —C(O)—, SC(O)—, —OC(O)—,        —N(R8)—(CH₂)_(s)—C(O)—, or —N(R6)—C(O)—;    -   W is —CR9,R10-;    -   R6, R7, and R8 each is, independently, H, C₁₋₁₀ alkyl,        substituted C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀        heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀        alkynyl, substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or        substituted akylaryl;    -   R9 and R10 each is, independently, H, C1, Br, I, F, C₁₋₁₀ alkyl,        substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀        heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀        alkynyl, substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or        substituted akylaryl; or R9 and R10 can, optionally, join        together to form a ring system;    -   R11 and R12 each is, independently, H, C₁₋₁₀ alkyl, substituted        C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl,        C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,        substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted        akylaryl;    -   i is 1-10, provided that when i is 1, then R1 is not H, C₁₋₄        alkyl, allyl, alkenyl or —CN, R4 is not H or —CH₃, R5 is not        C₁₋₅ alkyl group or a group of the formula of        —(CH₂)_(r)N(CH₃)_(v), R6, R7, R8, R9 and R10 each is,        independently, not H or C₁₋₅ alkyl, L is not -(Doc)t-, or X is        not H, Cl, Br, I, F, —CN, or C₁₋₅ alkyl;    -   m is 0 or 1;    -   n is 2-10;    -   p is 1-10;    -   q is 1-5;    -   r is 1-8;    -   s is 1-10;    -   t is 1-10;    -   v is 2-3;    -   Z is a ligand of at least one somatostatin receptor; or    -   a pharmaceutically acceptable salt thereof; and    -   wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group, carboxylic acid group, or hydroxyl        group of Z.

In a third embodiment of the first aspect, the chimeric analog of claim1, wherein said chimeric analog comprises formula (III),

wherein:

-   -   R2 is H, —N(R11)N(R12,R13), —N(R6R7), or —COOH;    -   R4 and R5 each is, independently, H, C₁₋₁₀ alkyl, substituted        C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl,        C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,        substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, substituted akylaryl        or R8-C(O)—;    -   W is —CR9R10- or —(CH₂)_(q)—NH—(CH₂)_(r)—;    -   R1, R6, R7, R8, R11, R12 and R13 each is, independently, H,        C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl,        substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀        alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl, aryl,        alkylaryl, or substituted akylaryl;    -   R9 and R10 each is, independently, H, —OH, —CN, —NO₂, F, Cl, Br,        I, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl,        substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀        alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl, akylaryl,        substituted alkylaryl, or aryl;    -   X is C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl,        substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀        alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl, akylaryl,        substituted alkylaryl, aryl, or acyl;    -   Q is C or N; provided that when Q is N, then R2 is absent;    -   i is 1-10;    -   n is 1-6;    -   q is 1-6;    -   r is 1-8;    -   Z is a ligand of at least one somatostatin receptor; or    -   a pharmaceutically acceptable salt thereof; and    -   wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group or hydroxyl group of Z.

In a fourth embodiment of the first aspect, the chimeric analogcomprises formula (IV),

wherein:

-   -   R1 and R2 each is, independently, H, C₁₋₁₀ alkyl, substituted        C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl,        C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,        substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted        akylaryl;    -   R3, R4, R5, R6 and R7 each is, independently, H, —OH, —CN, —NO₂,        F, Cl, Br, I, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀        heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,        substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀        alkynyl, aryl, alkylaryl, or substituted akylaryl;    -   W is —CR4R5-;    -   Y is —CR6R7)_(m)—C(O)— or acyl;    -   m is 0-10;    -   n is 1-6;    -   Z is a ligand of at least one somatostatin receptor; or    -   a pharmaceutically acceptable salt thereof; and    -   wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group or hydroxyl group of Z.

In a fifth embodiment of the first aspect, the chimeric analog comprisesformula (V),

wherein:

-   -   P is —N(R3R4) or H;    -   X is N or S;    -   W is —CR5R6-;    -   Y is —CR7R8)_(m)—C(O)—;    -   R1, R3 and R4 each is, independently, H, C₁₋₁₀ alkyl,        substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀        heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀        alkynyl, substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or        substituted akylaryl;    -   R2, R5, R6, R7 and R8 each is, independently, H, —OH, —CN, —NO₂,        F, Cl, Br, I, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀        heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,        substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀        alkynyl, aryl, alkylaryl, or substituted akylaryl;    -   i is 1-10;    -   m is 0-10;    -   n is 0-6;    -   Z is a ligand of at least one somatostatin receptor; or    -   a pharmaceutically acceptable salt thereof; and    -   wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group or hydroxyl group of Z.

In a sixth aspect of the first embodiment, the chimeric analog comprisesformula (VI),

wherein:

-   -   Y is —CR2R3)_(m)—C(O)— or acyl;    -   R1 is H, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀        heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,        substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀        alkynyl, aryl, alkylaryl, or substituted akylaryl;    -   R2 and R3 each is, independently, H, —OH, —CN, —NO₂, F, Cl, Br,        I, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl,        substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀        alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl, aryl,        alkylaryl, or substituted akylaryl;    -   i is 1-10;    -   m is 0-10;    -   Z is a ligand of at least one somatostatin receptor; or    -   a pharmaceutically acceptable salt thereof; and    -   wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group or hydroxyl group of Z.

In a seventh embodiment of the first aspect, the chimeric analogcomprises formula (VII),

wherein:

-   -   P is —N(R3R4) or H;    -   L is —(CR5R6)_(m)—C(O)— or acyl;    -   Y is C₁₋₁₀ afkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl,        substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀        alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl, aryl,        alkylaryl, substituted akylaryl, or absent;    -   R1, R2, R5 and R6 each is, independently, H, —OH, —CN, —NO₂, F,        Cl, Br, I, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀        heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,        substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀        alkynyl, aryl, alkylaryl, or substituted akylaryl;    -   R3 and R4 each is, independently, H, C₁₋₁₀ alkyl, substituted        C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl,        C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,        substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted        akylaryl;    -   i is 1-10;    -   m is 0-10;    -   Z is a ligand of at least one somatostatin receptor; or    -   a pharmaceutically acceptable salt thereof; and    -   wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group or hydroxyl group of Z.

In an eighth embodiment of the first aspect, the chimeric analogcomprises formula (VIII),

wherein:

-   -   X and Y each is, independently, —OH, —OR4 or R5-C(O)—O—;    -   L is —CR3R4)_(m)—C(O)— or acyl;    -   R1, R2, R3 and R4 each is, independently, H, —OH, F, C1, Br, I,        —CN, NO₂, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀        heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,        substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀        alkynyl, aryl, alkylaryl, or substituted akylaryl; or R2 and R3        can, optionally, join together to form a ring system;    -   R5 is H, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀        heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,        substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀        alkynyl, aryl, alkylaryl, or substituted akylaryl;    -   i is 1-10;    -   m is 0-10;    -   Z is a ligand of at least one somatostatin receptor; or    -   a pharmaceutically acceptable salt thereof; and        wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group or hydroxyl group of Z.

In a ninth embodiment of the first aspect, the chimeric analog comprisesformula (IX),

wherein:

-   -   X and Y each is, independently, —OH, —OR4 or R7-C(O)—;    -   Q is —(CR5R6)_(m)—C(O)— or acyl;    -   R1, R2, R3, R4, R5 and R6 each is, independently, H, —OH, F, Cl,        Br, I, —CN, NO₂, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀        heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,        substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀        alkynyl, aryl, alkylaryl, or substituted akylaryl; or R1 and R2        can, optionally, join together to form a ring system; or R3 and        R4 can, optionally, join together to form a ring system;    -   R7 is H, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀        heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,        substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀        alkynyl, aryl, alkylaryl, or substituted akylaryl;    -   i is 1-10;    -   m is 0-10;    -   Z is a ligand of at least one somatostatin receptor; or    -   a pharmaceutically acceptable salt thereof; and    -   wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group or hydroxyl group of Z.

In a tenth embodiment of the first aspect, the chimeric analog comprisesformula (X),

wherein:

-   -   Y is —(CR8R9)_(m)—C(O)— or acyl;    -   R1, R2, R3, R4, R5, R6, R7, R8 and R9 each is, independently, H,        —OH, F, Cl, Br, I, —CN, NO₂, C₁₋₁₀ alkyl, substituted C₁₋₁₀        alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀        alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted        C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl;    -   i is 1-10;    -   m is 0-10;    -   Z is a ligand of at least one somatostatin receptor; or    -   a pharmaceutically acceptable salt thereof; and    -   wherein each moiety depicted between the brackets is,        independently for each occurrence, attached to an N-terminal or        an internal amine group or hydroxyl group of Z.

In another embodiment of the first aspect, the chimeric analog comprisesany of the compounds listed in Table 1; or a pharmaceutically acceptablesalt thereof.

In another embodiment of the first aspect, the chimeric analog comprisesa compound according to the formula of:

-   -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,        or    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a preferred embodiment of the first aspect, the chimeric analogcomprises a compound according to the formula of:

-   -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂, or    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or    -   a pharmaceutically acceptable salt thereof.

In a more preferred embodiment of the first aspect, the chimeric analogcomprises a compound according to the formula ofDop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In another more preferredembodiment, the chimeric analog comprises a compound according to theformula of Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In yet another more preferredembodiment, the chimeric analog comprises a compound zccording to theformula of Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.

In another embodiment of the first aspect, the chimeric analog comprisesa compound according to the formula of:

-   -   Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],    -   Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or    -   Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a second aspect, the invention features a compound useful as anintermediate in a chemical synthesis, wherein said intermediatecomprises a compound according to formula (3), (6), (11), (14), (18),(21), (24), or (27) (referred to herein as intermediate compound (3),(6), (11), (14), (18), (21), (24), and (27), respectively) as shownbelow:

or an organic or inorganic salt thereof.

In a third aspect, the invention features a method of eliciting adopamine receptor agonist effect in a subject in need thereof, whereinsaid method comprises administering to said subject an effective amountof a chimeric analog of the invention, wherein said chimeric analoguecomprises a compound according to the formula of Formula (I), (II),(III), (IV), (V), (VI) (VII), (VIII), (IX), or (X), or apharmaceutically acceptable salt thereof, or intermediate compound (3),(6), (11), (14), (18), (21), (24), or (27), or an organic or inorganicsalt thereof; and wherein said effective amount is the amount effectiveto elicit a dopamine receptor agonist effect in said subject.

In a first embodiment of the third aspect, the chimeric analog comprisesany of the compounds listed in Table 1; or a pharmaceutically acceptablesalt thereof.

In a second embodiment of the third aspect, the chimeric analogcomprises a compound according to the formula of:

-   -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,        or    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a preferred embodiment, the chimeric analog comprises a compoundaccording to the formula of:

-   -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂, or    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or        a pharmaceutically acceptable salt thereof.

In a more preferred embodiment of the third aspect, the chimeric analogcomprises a compound according to the formula ofDop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.

In another more preferred embodiment of the third aspect, chimericanalogue comprises a compound according to the formula ofDop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In yet another more preferredembodiment of the third aspect, chimeric analogue comprises a compoundaccording to the formula ofDop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In a third embodiment of thethird aspect, the chimeric analogue comprises a compound according tothe formula of:

-   -   Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],[B153]    -   Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or    -   Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a fourth aspect, the invention features a method of eliciting asomatostatin receptor agonist effect in a subject in need thereof,wherein said method comprises administering to said subject an effectiveamount of a chimeric analogue of the invention, wherein said chimericanalogue comprises a compound according to the formula of Formula (I),(II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X), or apharmaceutically acceptable salt thereof, or intermediate compound (3),(6), (11), (14), (18), (21), (24), or (27), or an organic or inorganicsalt thereof; and wherein said effective amount is the amount effectiveto elicit a somatostatin receptor agonist effect in said subject.

In a first embodiment of the fourth aspect, the chimeric analoguecomprises any of the compounds listed in Table 1; or a pharmaceuticallyacceptable salt thereof.

In a second embodiment of the fourth aspect, the chimeric analoguecomprises a compound according to the formula of:

-   -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,        or    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a preferred embodiment, the chimeric analogue comprises a compoundaccording to the formula of:

-   -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂, or    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or        a pharmaceutically acceptable salt thereof.

In a more preferred embodiment of the fourth aspect, the chimeric analogcomprises a compound according to the formula ofDop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In another more preferredembodiment of the fourth aspect, chimeric analogue comprises a compoundaccording to the formula ofDop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In yet another more preferredembodiment of the fourth aspect, chimeric analogue comprises a compoundaccording to the formula ofDop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.

In a third embodiment of the fourth aspect, the chimeric analoguecomprises a compound according to the formula of:

-   -   Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],    -   Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or    -   Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a fifth aspect, the invention features a method of eliciting both adopamine receptor agonist effect and a somatostatin receptor agonisteffect in a subject in need thereof, wherein said method comprisesadministering to said subject an effective amount of a chimeric analogueof the invention, wherein said chimeric analogue comprises a compoundaccording to the formula of Formula (I), (II), (III), (IV), (V), (VI)(VII), (VIII), (IX), or (X), or a pharmaceutically acceptable saltthereof; or intermediate compound (3), (6), (11), (14), (18), (21),(24), or (27), or an organic or inorganic salt thereof; and wherein saideffective amount is the amount effective to elicit both a dopamine and asomatostatin receptor agonist effect in said subject.

In a first embodiment of the fifth aspect, the chimeric analoguecomprises any of the compounds listed in Table 1; or a pharmaceuticallyacceptable salt thereof.

In a second embodiment of the fifth aspect, the chimeric analoguecomprises a compound according to the formula of:

-   -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo [Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,        or    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a preferred embodiment, the chimeric analogue comprises a compoundaccording to the formula of:

-   -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂, or    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or        a pharmaceutically acceptable salt thereof.

In a more preferred embodiment of the fifth aspect, the chimeric analogcomprises a compound according to the formula ofDop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In another more preferredembodiment of the fifth aspect, chimeric analogue comprises a compoundaccording to the formula ofDop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In yet another more preferredembodiment of the fifth aspect, chimeric analogue comprises a compoundaccording to the formula ofDop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.

In a third embodiment of the fifth aspect, the chimeric analoguecomprises a compound according to the formula of:

-   -   Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],    -   Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or    -   Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a sixth aspect, the invention features a pharmaceutical compositioncomprising an effective amount of a compound according to the formula ofFormula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X),or a pharmaceutically acceptable salt thereof; or intermediate compound(3), (6), (11), (14), (18), (21), (24), or (27), or an organic orinorganic salt thereof; in a pharmaceutically acceptable carrier,wherein said effective amount is the amount effective to elicit adopamine receptor agonist effect or a somatostatin receptor agonisteffect or both in a subject in need thereof.

In a first embodiment of the sixth aspect, the chimeric analoguecomprises any of the compounds listed in Table 1; or a pharmaceuticallyacceptable salt thereof.

In a second embodiment of the sixth aspect, the chimeric analoguecomprises a compound according to the formula of:

-   -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo [Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,        or    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a preferred embodiment, the chimeric analogue comprises a compoundaccording to the formula of:

-   -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂, or    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or        a pharmaceutically acceptable salt thereof.

In a more preferred embodiment of the sixth aspect, the chimeric analogcomprises a compound according to the formula ofDop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In another more preferredembodiment of the sixth aspect, chimeric analogue comprises a compoundaccording to the formula ofDop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof. In yet another more preferredembodiment of the sixth aspect, chimeric analogue comprises a compoundaccording to the formula ofDop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.

In a third embodiment of the sixth aspect, the chimeric analoguecomprises a compound according to the formula of:

-   -   Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],    -   Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or    -   Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂;        or        a pharmaceutically acceptable salt thereof.

In a seventh aspect, the invention features a method of treating adisease or condition in a subject, said method comprising administeringto said subject a therapeutically effective amount of a chimeric analog,wherein said chimeric analog comprises a compound according to theformula of Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII),(IX), or (X); any of the compounds listed in Table 1;

-   -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],    -   Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or    -   Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂;        or a pharmaceutically acceptable salt thereof; or intermediate        compound (3), (6), (11), (14), (18), (21), (24), or (27); or an        organic or inorganic salt thereof; and wherein said disease or        disorder is selected from the list consisting of a        neuroendocrine tumor; a vascular disease; a connective tissue        disease; an immune disease; a disorder of the gastrointestinal        tract, pancreas, kidney, or liver; a metabolic disease; a        cachexia; cancer or a tumor of the lung, breast, prostate,        liver, thyroid, blood; a musculoskeletal disorder; a panic        disorder; and opioid overdose; and wherein said therapeutically        effective amount is the amount effective to treat said disease        or disorder in said patient.

In a first embodiment of the seventh aspect, the neuroendocrine tumor isa neuroendocrine tumor of the pituitary. In a first preferredembodiment, the neuroendocrine tumor of the pituitary is anACTH-producing tumor. Preferably, the ACTH-producing tumor is Cushing'sdisease. In a second preferred embodiment, the neuroendocrine tumor ofthe pituitary is a growth hormone producing tumor. Preferably, thegrowth hormone producing tumor is acromegaly. In a third preferredembodiment, the neuroendocrine tumor of the pituitary is aprolactin-producing tumor. Preferably, the prolactin-producing tumor isa prolactinoma. In a fourth preferred embodiment, the neuroendocrinetumor of the pituitary is hyperprolactinemia or prolactinemia. In afifth preferred embodiment, the neuroendocrine tumor of the pituitary isthyroid stimulating hormone (TSH) secreting tumor. In a sixth preferredembodiment, the neuroendocrine tumor of the pituitary is“nonfunctioning” pituitary adenoma. In a seventh preferred embodiment,the neuroendocrine tumor of the pituitary is gonadotropinoma.

In a second embodiment of the seventh aspect, the neuroendocrine tumoris carcinoid tumor. In a preferred embodiment, the carcinoid tumorcauses carcinoid syndrome. In a third embodiment of the seventh aspect,the neuroendocrine tumor is glucagonoma. In a fourth embodiment of theseventh aspect, the neuroendocrine tumor is small cell lung carcinoma.In a fifth embodiment of the seventh aspect, the neuroendocrine tumor isthyroid medullary carcinoma. In a sixth embodiment of the seventhaspect, the neuroendocrine tumor is VIPoma. In a seventh embodiment ofthe seventh aspect, the neuroendocrine tumor is insulinoma. In an eighthembodiment of the seventh aspect, the disorder of said vascular diseaseis inappropriate angiogenesis. In a ninth embodiment of the seventhaspect, the disorder of said vascular disease is restenosis. In a tenthembodiment of the seventh aspect, the disorder of said vascular diseaseis retinopathy. In a preferred embodiment, the retinopathy is diabeticretinopathy or proliferative retinopathy. In another preferredembodiment, the retinopathy is macular degeneration, preferably,age-related macular degeneration.

In another embodiment of the seventh aspect, the connective tissuedisease is scleroderma. In yet another embodiment of the seventh aspect,the immune disease is rheumatoid arthritis. In yet another embodiment ofthe seventh aspect, the immune disease is inflammation. In yet anotherembodiment of the seventh aspect, the immune disease is fibrosis. In yetanother embodiment of the seventh aspect, the immune disease is Graves'opthalmopathy. In yet another embodiment of the seventh aspect, theimmune disease is allograft rejection. In yet another embodiment of theseventh aspect, the disorder of the gastrointestinal tract comprisesgastric acid secretion, peptic ulcers, inflammatory bowel disease (IBD),or diarrhea. In a preferred embodiment, the IBD is irritable bowelsyndrome or Crohn's disease. In another preferred embodiment, thediarrhea is AIDS related or chemotherapy related or watery diarrheasyndrome. In yet another preferred embodiment, the disorder of thegastrointestinal tract is small bowel syndrome, small bowel obstruction,gastroesophageal reflux, duodenogastric reflux, H. pylori proliferation,or gastrointestinal bleeding.

In yet another embodiment of the seventh aspect, the metabolic diseasecomprises hyperlipidemia, insulin resistance, Syndrome X, obesity,diabetes, or a diabetes-related disease. In a preferred embodiment, thediabetes-related disease comprises diabetic nephropathy, diabeticneuropathy, diabetic retinopathy, or gastroparesis.

In yet another embodiment of the seventh aspect, the cachexia is cardiaccachexia, cancer cachexia, or geriatric cachexia.

In yet another embodiment of the seventh aspect, the disease or disordercomprises glioma, anorexia, hypothyroidism, Graves' disease,hyperaldeosteronism, systemic sclerosis, pancreatitis, external andinternal pancreatic pseudocysts and ascites, pancreaticocutaneousfistula, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-EllisonSyndrome, gastrointestinal hormone secreting tumor, dawn phenomenon,dumping syndrome, hyperparathyroidism, Paget's disease, polycystic ovarydisease, orthostatic hypotension, postprandial hypotension, portalhypertension, angiopathy, or graft vessel bleeding.

In a first related embodiment of the aspect of the invention disclosedabove, the chimeric analog comprises a SSTR-1 agonist and a dopaminereceptor agonist; or a pharmaceutically acceptable salt thereof. In afirst preferred embodiment, the chimeric analog further comprises aSSTR-2 agonist or a SSTR-3 agonist, or a pharamaceutically acceptablesalt thereof, or both.

In a second preferred embodiment, the chimeric analog further comprisesa SSTR-5 agonist, or a pharmaceutically acceptable salt thereof. In athird preferred embodiment, the chimeric analog further comprises aSSTR-2 agonist or a SSTR-3 agonist, or a pharmaceutically acceptablesalt thereof.

In a more preferred embodiment, the chimeric analog comprises a SSTR-1agonist and a dopamine receptor agonist and further comprises a SSTR-2agonist, a SSTR-3 agonist, and a SSTR-5 agonist, or a pharmaceuticallyacceptable salt thereof. In a second related embodiment of the aspect ofthe invention disclosed above, the chimeric analog comprises a SSTR-2agonist and a dopamine receptor agonist; or a pharmaceuticallyacceptable salt thereof. In a preferred embodiment, the chimeric analogfurther comprises a SSTR-5 agonist, or a pharmaceutically acceptablesalt thereof.

In a third related embodiment of the aspect of the invention disclosedabove, the chimeric analog comprises a SSTR-3 agonist and a dopaminereceptor agonist; or a pharmaceutically acceptable salt thereof.

In a fourth related embodiment of the aspect of the invention disclosedabove, the chimeric analog comprises a SSTR-5 agonist and a dopaminereceptor agonist; or a pharmaceutically acceptable salt thereof.

In an eighth aspect, the invention features a method of treatingacromegaly in a subject in need thereof, wherein said method comprisesadministering to said subject a therapeutically effective amount of achimeric analog, wherein said chimeric analog comprises a compoundaccording to the formula of Formula (I), (II), (III), (IV), (V), (VI)(VII), (VIII), (IX), or (X); any of the compounds listed in Table 1;

-   -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],    -   Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or    -   Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂;        or a pharmaceutically acceptable salt thereof; or intermediate        compound (3), (6), (11), (14), (18), (21), (24), or (27); or an        organic or inorganic salt thereof, and the therapeutically        effective amount is the amount effective to treat acromegaly in        said patient. In a preferred embodiment of this aspect of the        invention, the chimeric analog comprises a SSTR-5 agonist and a        dopamine receptor agonist. More preferably, the chimeric analog        further comprises a SSTR-2 agonist.

In another preferred embodiment of this aspect, the subject hasdeveloped or is at risk of developing acromegaly.

In a ninth aspect, the invention features a method of treatingprolactinemia in a subject in need thereof, wherein said methodcomprises administering to said subject a therapeutically effectiveamount of a chimeric analog, wherein said chimeric analog comprises acompound according to the formula of Formula (I), (II), (III), (IV),(V), (VI) (VII), (VIII), (IX), or (X); any of the compounds listed inTable 1;

-   -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,    -   Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DPhe-cyclo [Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,    -   Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],    -   Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or    -   Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂;        or a pharmaceutically acceptable salt thereof; or intermediate        compound (3), (6), (11), (14), (18), (21), (24), or (27); or an        organic or inorganic salt thereof; and the therapeutically        effective amount is the amount effective to treat prolactinemia        in said patient. In a preferred embodiment of this aspect of the        invention, the chimeric analog comprises a SSTR-5 agonist and a        dopamine receptor agonist. More preferably, the chimeric analog        further comprises a SSTR-2 agonist.

In another preferred embodiment of this aspect, the subject hasdeveloped or is at risk of developing prolactinemia.

In some embodiments, compounds of the invention may include thestructure of DopA-Lys(DopA), wherein Lys is L-lysine, unless expresslydesignated as DLys. A is 1-13, for example, Dop1, Dop2, Dop3, Dop4,Dop5, Dop6, Dop7, Dop8, Dop9, Dop10, Dop11, Dop12, and Dop13. Thestructure of a DopA-Lys(DopA), in which A is 2 (i.e., Dop2-Lys(Dop2)),and in which A is 5 (i.e., Dop5-Lys(Dop5)), are shown below.

By “Dop1” is meant a compound having the structure of:

By “Dop2” is meant a compound having the structure of:

By “Dop3” is meant a compound having the structure of:

By “Dop4” is meant a compound having the structure of:

By “Dop5” is meant a compound having the structure of:

By “Dop6” is meant a compound having the structure of:

By “Dop7” is meant a compound having the structure of:

By “Dop8” is meant a compound having the structure of:

By “Dop9” is meant a compound having the structure of:

By “Dop10” is meant a compound having the structure of:

By “Dop11” is meant a compound having the structure of:

By “Dop12” is meant a compound having the structure of:

By “Dop13” is meant a compound having the structure of:

Lys(Dop2) has the structure of:

Dop2-Lys(Dop2) has the structure of:

Lys(Dop5) has the structure of:

Dop5-Lys(Dop5) has the structure of:

By “Alkyl” is meant a hydrocarbon group containing one or more carbonatoms, where multiple carbon atoms if present are joined by singlebonds. The alkyl hydrocarbon group may be straight-chain or contain oneor more branches or cyclic groups.

By “Substituted alkyl” is meant an alkyl wherein one or more hydrogenatoms of the hydrocarbon group are replaced with one or moresubstituents selected from the group consisting of halogen (i.e.,fluorine, chlorine, bromine, and iodine), —OH, —CN, —SH, —NH₂, —NHCH₃,—NO₂, —C₁₋₂ alkyl substituted with 1 to 5 halogens, —CF₃, —OCH₃, —OCF₃,and —(CH₂)₀₋₄—COOH. In different embodiments 1, 2, 3 or 4 substituentsare present. The presence of —(CH₂)₀₋₄—COOH results in the production ofan alkyl acid. Examples of alkyl acids containing, or consisting of,—(CH₂)₀₋₄—COOH include 2-norbornane acetic acid, tert-butyric acid and3-cyclopentyl propionic acid.

By “Heteroalkyl” is meant an alkyl wherein one of more of the carbonatoms in the hydrocarbon group are replaced with one or more of thefollowing groups: amino, amido, —O—, or carbonyl. In differentembodiments 1 or 2 heteroatoms are present.

By “Substituted heteroalkyl” is meant a heteroalkyl wherein one or morehydrogen atoms of the hydrocarbon group are replaced with one or moresubstituents selected from the group consisting of halogen, (i.e.,fluorine, chlorine, bromine, and iodine), —OH, —CN, —SH, —NH₂, —NHCH₃,—NO₂, —C₁₋₂ alkyl substituted with 1 to 5 halogens, —CF₃, —OCH₃, —OCF₃,and —(CH₂)₀₋₄—COOH. In different embodiments 1, 2, 3 or 4 substituentsare present.

By “Alkenyl” is meant a hydrocarbon group made up of two or more carbonswhere one or more carbon-carbon double bonds are present. The alkenylhydrocarbon group may be straight-chain or contain one or more branchesor cyclic groups.

“Substituted alkenyl” refers to an alkenyl where one or more hydrogensare replaced with one or more substituents selected from the groupconsisting of halogen (i.e., fluorine, chlorine, bromine, and iodine),—OH, —CN, —SH, —NH₂, —NHCH₃, —NO₂, —C₁₋₂ alkyl substituted with 1 to 5halogens, —CF₃, —OCH₃, —OCF₃, and —(CH₂)₀₋₄—COOH. In differentembodiments 1, 2, 3 or 4 substituents are present.

By “Alkynyl” is meant to a hydrocarbon group made up of two or morecarbons where one or more carbon-carbon triple bonds are present. Thealkynyl hydrocarbon group may be straight-chain or contain one or morebranches or cyclic groups.

By “Substituted alkynyl” is meant an alkynyl where one or more hydrogensare replaced with one or more substituents selected from the groupconsisting of a halogen (i.e., fluorine, chlorine, bromine, and iodine),—OH, —CN, —SH, —NH₂, —NHCH₃, —NO₂, —C₁₋₂ alkyl substituted with 1 to 5halogens, —CF₃, —OCH₃, —OCF₃, and —(CH₂)₀₋₄—COOH. In differentembodiments 1, 2, 3 or 4 substituents are present.

By “Aryl” is meant an optionally substituted aromatic group with atleast one ring having a conjugated pi-electron system, containing up totwo conjugated or fused ring systems. Aryl includes carbocyclic aryl,heterocyclic aryl and biaryl groups. Preferably, the aryl is a 5 or 6membered ring. Preferred atoms for a heterocyclic aryl are one or moresulfur, oxygen, and/or nitrogen. Examples of aryl include phenyl,1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, and9-anthracene. Aryl substituents are selected from the group consistingof —C₁₋₄ alkyl, —C₁₋₄ alkoxy, halogen (i.e., fluorine, chlorine,bromine, and iodine), —OH, —CN, —SH, —NH₂, —NO₂, —C₁₋₂ alkyl substitutedwith 1 to 5 halogens, —CF₃, —OCF₃, and —(CH₂)₀₋₄—COOH. In differentembodiments the aryl contains 0, 1, 2, 3, or 4 substituents.

By “Acyl” is meant X′−R″−C(O)—, where R″ is alkyl, substituted alkyl,heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl,alkynyl, substituted alkynyl, aryl, alkylaryl, or substituted alklyaryland X′ is H or absent.

By “Arylalkyl” or “alkylaryl” is meant an “alkyl” joined to an “aryl”.

By “Abu” is meant α-aminobutyric acid.

By “Aepa” is meant 4-(2-aminoethyl)-1-carboxy methyl-piperazine,represented by the structure:

By “Aib” is meant α-aminoisobutyric acid.

By “Ala” or A” is meant alanine.

By “β-Ala” is meant beta-alanine.

By “Arg” or “R” is meant arginine.

By “Asn” or “N” is meant asparagine.

By “Asp or “D” is meant aspartic acid.

By “Caeg” is meant N-(2-aminoethyl)-N-(2-cytosinyl-1-oxo-ethyl)-glycine,represented by the structure:

By “Cys” or “C” is meant cysteine.

By “Dab” is meant 2,4-diaminobutyric acid.

By “Doc” is meant 8-amino-3,6-dioxaoctanoic acid, represented by thestructure

By “Gln” or “Q” is meant glutamine.

By “Glu” or “E” is meant glutamic acid.

By “Gly” or “G” is meant glycine.

By “His” or “H” is meant histidine.

By “Ile” or “I” is meant isoleucine.

By “Leu” or “L” is meant leucine.

By “Lys” or K” is meant lysine.

By “Met” or “M”is meant methionine.

By “1Nal”is meant β-(1-naphthyl)alanine.

By “2Nal”is meant β-(2-naphthyl)alanine.

By “Nle”is meant norleucine.

By “Om”is meant onithine.

By “2Pal”is meant β-(2-pyridinyl)alanine.

By “3Pal”is meant β-(3-pyridinyl)alanine.

By “4Pal”is meant β-(4-pyridinyl)alanine.

By “Phe” or “F”is meant phenylalanine.

By “Pro” or “P”is meant proline.

By “Ser” or “S”is meant serine.

By “Thr” or “T” is meant threonine.

By “Thr-ol” is meant threoninol, represented by the structure:

By “Trp” or “W” is meant tryptophan.

By “Tyr” or “Y” is meant tyrosine.

By “3ITyr” is meant 3-iodo-tyrosine.

3ITyr(Dop2) has the structure of:

By “Val” or “V” is meant valine.

By “(N-Me)Trp” “is meant N-α-methyl-tryptophan.

Certain other abbreviations used herein are defined as follows:

By “Ac” is meant acetyl.

By “Boc” is meant tert-butyloxycarbonyl.

By “Bzl” is meant benzyl.

By “DCM” is meant dichloromethane.

By “DIC” is meant N,N-diisopropylcarbodiimide.

By “DIEA” is meant diisopropylethyl amine.

By “Dmab” is meant4-{N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)-amino}benzyl.

By “DMAP” is meant 4-(dimethylamino)pyridine.

By “DMF” is meant dimethylformamide.

By “DNP” is meant 2,4-dinitrophenyl.

By “Fmoc” is meant Fluorenylmethyloxycarbonyl.

By “HBTU” is meant 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate.

By “cHex” is meant cyclohexyl.

By “HOAT” is meant O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate.

By “HOBt” is meant 1-hydroxy-benzotriazole.

By “Mmt” is meant 4-methoxytrityl.

By “NMP” is meant N-methylpyrrolidone.

By “Pbf” is meant 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl.

By “tBu” is meant tert-butyl.

By “TIS” is meant triisopropylsilane.

By “TOS” is meant tosyl.

By “trt” is meant trityl.

By “TFA” is meant trifluoro acetic acid.

By “TFFH” is meant tetramethylfluoroforamidinium hexafluorophosphate.

By a “somatostatin receptor agonist” is meant a compound that has a highbinding affinity (e.g., Ki of less than 100 nM, or preferably less than10 nM, or more preferably less than 1 nM) for a somatostatin receptor(e.g., as defined by the receptor binding assay described below), suchas any of the different subtypes: e.g., SSTR-1, SSTR-2, SSTR-3, SSTR-4,and SSTR-5, and elicits a somatostatin-like effect; for example, in anassay for the inhibition of cAMP intracellular production.

By a “somatostatin selective agonist” is meant a somatostatin receptoragonist which has a higher binding affinity (i.e., lower Ki) for onesomatostatin receptor subtype than for any other somatostatin receptorsubtype, such as, for example, a somatostatin SSTR-2 selective agonist.

By a “dopamine receptor agonist” is meant a compound that has a highbinding affinity (e.g., Ki of less than 100 nM, or preferably less than10 nM, or more preferably less than 1 nM) for a dopamine receptor (e.g.,as defined by the receptor binding assay described below), such as anyof the different subtypes: e.g., D1, D2, D3, D4, and D5 receptors.

DETAILED DESCRIPTION

The invention features somatostatin-dopamine chimeric analogs andmethods relating to their therapeutic use for the treatment ofneoplasia, acromegaly, and other conditions.

Various somatostatin receptors (SSTR's) have been isolated (e.g.,SSTR-1, SSTR-2, SSTR-3, SSTR-4, and SSTR-5). Somatostatin agonists arethose compounds that bind to at least one SSTR (e.g., SSTR-1 agonist,SSTR-2 agonist, SSTR-3 agonist, SSTR-4 agonist or a SSTR-5 agonist).

Further examples of somatostatin agonists are those covered by formulaeor those specifically recited in the publications set forth below, eachof which is hereby incorporated by reference in its entirety.

-   -   PCT Publication No. WO 03/057214 (2003)    -   U.S. Application No. 20030191134 (2003)    -   U.S. Application No. 20030083241 (2003)    -   PCT Publication No. WO 02/10215 (2002)    -   U.S. Pat. No. 6,316,414 (2001)    -   PCT Publication No. WO 99/22735 (1999)    -   PCT Publication No. WO 98/08100 (1998)    -   PCT Publication No. WO 98/44921 (1998)    -   PCT Publication No. WO 98/45285 (1998)    -   PCT Publication No. WO 98/44922 (1998)    -   EP Application No. PS 164 EU (Inventor: G. Keri);    -   Van Binst, G. et al. Peptide Research 5:8 (1992);    -   Horvath, A. et al. Abstract, “Conformations of Somatostatin        Analogs Having Antitumor Activity”, 22nd European peptide        Symposium, Sep. 13-19, 1992, Interlaken, Switzerland;    -   PCT Publication No. WO 91/09056 (1991);    -   EP Application No. 0 363 589 A2 (1990);    -   U.S. Pat. No. 4,904,642 (1990);    -   U.S. Pat. No. 4,871,717 (1989);    -   U.S. Pat. No. 4,853,371 (1989);    -   U.S. Pat. No. 4,725,577 (1988);    -   U.S. Pat. No. 4,684,620 (1987);    -   U.S. Pat. No. 4,650,787 (1987);    -   U.S. Pat. No. 4,603,120 (1986);    -   U.S. Pat. No. 4,585,755 (1986);    -   EP Application No. 0 203 031 A2 (1986);    -   U.S. Pat. No. 4,522,813 (1985);    -   U.S. Pat. No. 4,486,415 (1984);    -   U.S. Pat. No. 4,485,101 (1984);    -   U.S. Pat. No. 4,435,385 (1984);    -   U.S. Pat. No. 4,395,403 (1983);    -   U.S. Pat. No. 4,369,179 (1983);    -   U.S. Pat. No. 4,360,516 (1982);    -   U.S. Pat. No. 4,358,439 (1982);    -   U.S. Pat. No. 4,328,214 (1982);    -   U.S. Pat. No. 4,316,890 (1982);    -   U.S. Pat. No. 4,310,518 (1982);    -   U.S. Pat. No. 4,291,022 (1981);    -   U.S. Pat. No. 4,238,481 (1980);    -   U.S. Pat. No. 4,235,886 (1980);    -   U.S. Pat. No. 4,224,199 (1980);    -   U.S. Pat. No. 4,211,693 (1980);    -   U.S. Pat. No. 4,190,648 (1980);    -   U.S. Pat. No. 4,146,612 (1979);    -   U.S. Pat. No. 4,133,782 (1979);    -   U.S. Pat. No. 5,506,339 (1996);    -   U.S. Pat. No. 4,261,885 (1981);    -   U.S. Pat. No. 4,728,638 (1988);    -   U.S. Pat. No. 4,282,143 (1981);    -   U.S. Pat. No. 4,215,039 (1980);    -   U.S. Pat. No. 4,209,426 (1980);    -   U.S. Pat. No. 4,190,575 (1980);    -   EP Patent No. 0 389 180 (1990);    -   EP Patent No. 0 505 680 (1982);    -   EP Patent No. 0 083 305 (1982);    -   EP Patent No. 0 030 920 (1980);    -   PCT Publication No. WO 88/05052 (1988);    -   PCT Publication No. WO 90/12811 (1990);    -   PCT Publication No. WO 97/01579 (1997);    -   PCT Publication No. WO 91/18016 (1991);    -   U.K. Application No. GB 2,095,261 (1981); and    -   French Application No. FR 2,522,655 (1983).

Note that for all somatostatin agonists described herein, each aminoacid residue represents the structure of —NH—C(R)H—CO—, in which R isthe side chain (e.g., CH₃ for Ala). Lines between amino acid residuesrepresent peptide bonds that join the amino acids. Also, where the aminoacid residue is optically active, it is the L-form configuration, unlessthe D-form is expressly designated. For clarity, disulfide bonds (e.g.,disulfide bridge) that exist between two free thiols of Cys residues arenot shown. Abbreviations of the common amino acids are in accordancewith IUPAC-IUB recommendations.

Synthesis of Somatostatin Agonists

The methods for synthesizing peptide somatostatin agonists are welldocumented and are within the ability of a person of ordinary skill inthe art. For example, peptides are synthesized on Rink amide MBHA resin(4-(2′4′-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucyl-MBHAresin) using a standard solid phase protocol of Fmoc chemistry. Thepeptide-resin with free amino functional at the N-terminus is thentreated with the corresponding compound containing dopamine moiety. Thefinal product is cleaved off from resin with TFAwater/triisopropylsilane (TIS) mixture.

For example, synthesis of H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH₂, canbe achieved by following the protocol set forth in Example I of EuropeanPatent Application 0 395 417 A1. The synthesis of somatostatin agonistswith a substituted N-terminus can be achieved, for example, by followingthe protocol set forth in PCT Publication No. WO 88/02756, PCTPublication No., WO 94/04752, and/or European Patent Application No. 0329 295.

Peptides can be and were cyclized by using iodine solution in MeOH/waterand purified on C18 reverse-phase preparative HPLC, usingacetonitrile-0.1% TFA/water-0.1% TFA buffers. Homogeneity was assessedby analytical HPLC and mass spectrometry and determined to be>95% foreach peptide.

Certain uncommon amino acids were purchased from the following vendors:Fmoc-Doc-OH and Fmoc-AEPA-OH were purchased from Chem-ImpexInternational, Inc. (Wood Dale, Ill., USA). Fmoc-Caeg (Bhoc)-OH waspurchased from PerSeptive Biosystems (Framingham, Mass., USA). Bhocstands for benzhydryloxycarbonyl.

Synthesis of Dopamine Agonists

The methods for synthesizing many dopamine agonists are also welldocumented and are within the ability of a person of ordinary skill inthe art. Further synthetic procedures are provided in the followingreaction schemes and examples.

Synthesis of Somatostatin-Dopamine Chimers

Somatostatin-dopamine chimers may be synthesized according to thefollowing reaction schemes and examples. Starting material andintermediates for such compounds are commercially available or areprepared using standard methods, e.g., see Pharmazie 39, 537 (1984);collect Czech. Chem. Commun. 33, 577 (1966); Helv. Chim. Acta 32, 1947,(1949), U.S. Pat. No. 5,097,031; U.S. Pat. No. 3,901,894; EP 0003667;and U.S. Pat. No. 4,526,892. Methods for the synthesis of peptides areknown to the skilled artisan (e.g., see Stewart et al., Solid PhaseSynthesis, Pierce Chemical, 2^(nd) Ed. 1984; G. A. Grant; Syntheticpeptide; W H., Freenand Co., New York, 1992; M. Bodenszky A. Bodanszky,The Practice of Peptide Synthesis, Spring Venlag. N.Y. 1984).

Other somatostatin-dopamine chimers that suppress growth hormone andprolactin secretion and are useful in the treatment of acromegaly aredescribed in Saveanu et al. (J. Clin. Endocrin. and Metab. 87:5545-5552,2002), hereby incorporated by reference.

The following examples are provided to illustrate the invention. Theyare not meant to limit the invention in any way.

EXAMPLE 1 Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂

The Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂peptide was automatically synthesized on an ACT 396 peptide synthesizer(Advanced ChemTech, Louisville, Ky.) using Fluorenylmethyloxycarbonyl(Fmoc) chemistry. A RINK AMIDE 4-methylbenzylhydrylamine (MBHA) resin(Novabiochem., San Diego, Calif.) with substitution of 0.66 mmol/g wasused (sub: 0.66 mmol/g, 76 mg, 50 μmol scale). The Fmoc amino acids usedare Fmoc-DTrp(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Thr(But)-OH, Fmoc-DPhe-OH,Fmoc-Cys(Trt)-OH, and Fmoc-DLys(Dde))-OH from NOVABIOCHEM (San Diego,Calif.) and Fmoc-3ITyr-OH from CHEM-IMPEX INTERNATIONAL, Inc. (WoodDale, Ill.). The synthesis was carried out on a 50 μmol scale. For eachreaction cycle, the ACT 396 peptide synthesizer was programmed toperform: (1) washing with N-methylpyrrolidone (NMP) twice; (2) removingFmoc protecting group with 20% piperidine in NMP for 1×5 min and 1×25min; (3) washing with NMP twice; and (4) double coupling with 4×foldexcess of Fmoc protected amino acid (0.20 mmol), HOBt (0.2 mmol), andN,N′-diisopropylcarboduimide (DIC) (0.2 mmol) in N,N-dimethylformamide(DMF) for 1 hour per coupling. The resin was coupled successivelyaccording to the sequence.

After the peptide chain was assembled, the Fmoc group was removed andthe resin was washed completely using NMP and dichloromethane (DCM). Theresin was transferred into a reaction vessel on a shaker and treatedwith 2% hydrozine in DMF for 2×30 minutes to remove Dde protecting groupin the side chain of DLys. After washing successively with DMF, MeOH andDCM, the resin was shaken overnight with Dop2-OH (54 mg, 3.0 eq),bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBrop, 82 mg,3.4 eq), 1-hydroxy-7-azabenzotriazole (HOAT, 0.4 mg, 3.0 eq),pentalflurophenol (18.4 mg, 4 eq), DMAP (0.25 mL of 0.1 M in DMF, 1.0eq) and diisopropylethyl amine (DIEA) (53 μL, 4 eq).

After washing successively with DMF, MeOH and DCM, the resin was treatedwith a mixture of TFA (4.75 mL), H₂O (0.4 mL), and triisopropylsilane(TIS, 0.425 mL) for 2 hours. The resin was removed by filtration. Thefiltrate was poured into 70 mL of ether. The precipitate formed wasfiltered off and washed thoroughly with ether. This crude product wasdissolved in 5 mL of aqueous acetic acid solution (water/aceticacid=1:1). The solution was then diluted with 50 mL of H₂O and 20 mL ofacetonitrile, to which was added, dropwise, iodine in methanol until thesolution acquired a sustained yellow hue. The solution was stirredslowly for 1 hour and the reaction was terminated by adding aqueousNa₂S₂O₃ solution. The crude product was purified on reverse-phasepreparative HPLC using a column of C18 DYNAMAX-100A° (4×43 cm, Varian,Walnut Creek, Calif.). The column was eluted with a liner gradient from90% A and 10% B to 60% A and 40% B in an hour where A was 0.1% TFA inwater and B was 0.1% TFA in acetonitrile. Fractions containing a majorcomponent by ultraviolet (UV) absorption were pooled and lyophilized.The purity was 95.7% based on an analytical HPLC analysis. Electro-sprayionization mass spectrometry (ESI mass) analysis gave the molecularweight at 1982.6 (in agreement with the calculated molecular weight of1983.3).

EXAMPLE 2Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂

The Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂compound was synthesized substantially according to the proceduredescribed for the synthesis ofDop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂ (asdescribed above in Example 1) with the following changes. After theassembly of the peptide chain, the resin was transferred into a reactionvessel on a shaker and treated with 25% piperidine in DMF for 30 minutesto remove the Fmoc protecting group at the N-terminus. After washingsuccessively with DMF, MeOH and DCM, the resin was shaken overnight withDop2-OH (3.0 eq), PyBrop (3.4 eq), HOAT (3.0 eq), DMAP (1.0 eq) and DIEA(4 eq). After cleavage and purification, the desired product was foundto have a purity of 95% based on an analytical HPLC analysis. ESI massanalysis gave the molecular weight at 2145.9 (in agreement with thecalculated molecular weight of 2145.6).

EXAMPLE 3Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂

The titled compound was synthesized substantially according to theprocedure described for the synthesis ofDop2-DPhe-Doc-DPhe-c[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂(described above in Example 2) except that Fmoc-Lys(Fmoc)-OH was usedfor the coupling of the last Lys residue at the N-terminus. The productwas found to be homogenous and the purity was 93.9% by HPLC. ESI massanalysis gave the molecular weight at 2020.9 (in agreement with thecalculated molecular weight of 2020.1).

EXAMPLE 4 Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂

The titled compound was synthesized substantially according to theprocedure described for the synthesis ofDop2-DPhe-Doc-DPhe-c[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂(described above in Example 1). The purity of the final product was93.9% based on an analytical HPLC analysis. ESI mass analysis gave themolecular weight at 1514.50 (in agreement with the calculated molecularweight of 1514.63).

EXAMPLE 5 Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂

The titled compound was synthesized substantially according to theprocedure described for the synthesis ofDop2-DPhe-Doc-DPhe-c[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂(described above in Example 2) except that Fmoc-DLys(Fmoc)-OH was usedfor the coupling of the last Lys residue at the N-terminus. The productwas found to be homogenous and the purity was 99.9% by HPLC. ESI massanalysis gave the molecular weight at 1693.6 (in agreement with thecalculated molecular weight of 1694.23).

EXAMPLE 6 Synthesis of Intermediate Compound (3)

A mixture of R(−)norapomorphine compound 1 (from Sigma, 200 mg, 0.79mmol) and p-toluenesulfonic acid monohydrate (451 mg, 2.37 mmol) inacetone (20 mL) is stirred at room temperature overnight. The solvent isremoved under reduced pressure. The residue is dissolved in methylenechloride (30 mL) and washed with saturated NaHCO₃ aqueous solution (2times) and brine (2 times), dried over anhydrous MgSO₄, filtered, andconcentrated in vacuo. The residue is purified by using columnchromatography on silica, yielding acetonide- R(−)norapomorphine,yielding compound 2.

To a mixture of compound 2 (167 mg, 0.57 mmol) andN,N-diisopropylethylamine (219 mg, 1.7 mmol) in methylene chloride (20mL) is added dropwise bromoacetic acid (236 mg, 1.7 mmol) at 0° C. Themixture is then warmed to room temperature and stirred for 6 hours. Thesolution is washed with brine (2 times), dried over anhydrous MgSO₄,filtered, and concentrated in vacuo. The residue is purified by usingcolumn chromatography on silica, yielding intermediate compound 3.

EXAMPLE 7 Synthesis of intermediate compound (6)

The mixture of R(−)norapomorphine 4 (200 mg, 0.748 mmol),2-methylpropene (83.9 mg, 1.50 mmol), and a catalytic amount ofconcentrated H₂SO₄ in CH₂Cl₂ (20 mL) is stirred at room temperatureovernight. The solution is washed with saturated NaHCO₃ in aqueoussolution (2 times) and brine (2 times), dried over anhydrous MgSO₄,filtered, and concentrated in vacuo. The residue is purified by usingcolumn chromatography on silica, yielding compound 5.

To a mixture of compound 5 (150 mg, 0.486 mmol) andN,N-diisopropylethylamine (188 mg, 1.46 mmol) in methylene chloride (20mL) is added dropwise bromoacetic acid (203 mg, 1.46 mmol) at 0° C. Themixture is then warmed to room temperature and stirred for 6 hours. Thesolution is washed with brine (2 times) and dried over anhydrous MgSO₄,filtered, and concentrated in vacito. The residue is purified by usingcolumn chromatography on silica, yielding intermediate compound 6.

EXAMPLE 8 Synthesis of intermediate compound (11)

To a mixture of indolone 10 (WO 9415918, 218 mg, 1.00 mmol) andN,N-diisopropylethylamine (258 mg, 2.0 mmol) in methylene chloride (20mL) is added 4-iodobutyric acid (214 mg, 1.0 mmol). The resultingsolution is stirred at room temperature overnight. The solution isconcentrated in vacuo. The residue is purified by using columnchromatography on silica, yielding intermediate compound 11.

EXAMPLE 9 Synthesis of intermediate compound (14)

To a mixture of 1-adamantanamine hydrochloride 12 (Aldrich, 187 mg, 1.00mmol) and N,N-diisopropylethylamine (387 mg, 3.0 mmol) in methylenechloride (20 mL) is added 4-iodobutyric acid (214 mg, 1.0 mmol). Theresulting solution is stirred at room temperature overnight. Thesolution is washed with brine (2 times), dried over anhydrous MgSO₄,filtered, and concentrated in vacuo. The residue is purified by usingcolumn chromatography on silica, yielding compound 13.

To a solution of compound 13 (190 mg, 0.8 mmol) in dioxane (6 mL) andwater (3 mL) is added 1N NaOH (1.0 mL) at 0° C. To the resultingsolution is added di-tert-butyl dicarbonate (192 mg, 0.88 mmol) over 30min. The mixture is stirred at room temperature for 12 hours. Dioxane isremoved under reduced pressure. To the resulting water solution is addedethyl acetate. The pH of the solution is adjusted to about pH 3 byadding 0.2 N HCl solution at 0° C. The organic layer is separated,washed with water (twice), dried over anhydrous MgSO₄, filtered, andconcentrated in vacuo. The residue is purified by using columnchromatography on silica, yielding intermediate compound 14.

EXAMPLE 10 Synthesis of intermediate compound (18)

The mixture of fenoldopam 15 (from Sigma, 306 mg, 1.00 mmol) andp-toluenesulfonic acid monohydrate (476 mg, 2.50 mmol) in acetone (30mL) is stirred at room temperature overnight. The solvent is removedunder reduced pressure. The residue is dissolved in methylene chloride(30 mL) and washed with saturated NaHCO₃ aqueous solution (2 times) andbrine (2 times), dried over anhydrous MgSO₄, filtered, and concentratedin vacuo. The residue is purified by using column chromatography onsilica, yielding acetonide-fenoldopam 16.

A mixture of acetonide-fenoldopam 16 (277 mg, 0.80 mmol),2-methylpropene (67.0 mg, 1.20 mmol), and a catalytic amount ofconcentrated H₂SO₄ in CH₂Cl₂ (20 mL) is stirred at room temperatureovernight. The solution is washed with saturated NaHCO₃ aqueous solution(2 times) and brine (2 times) and dried over anhydrous MgSO₄, filteredand concentrated in vacuo. The residue is purified by using columnchromatography on silica, yielding compound 17.

To a mixture of 17 (201 mg, 0.50 mmol) and N,N-diisopropylethylamine(129 mg, 1.0 mmol) in methylene chloride (20 mL) is added 4-iodobutyricacid (107 mg, 0.5 mmol). The resulting solution is stirred at roomtemperature overnight. The solution is washed with brine (2 times),dried over anhydrous MgSO₄, filtered and concentrated in vacuo. Theresidue is purified by using column chromatography on silica, yieldingintermediate compound 18.

EXAMPLE 11 Synthesis of intermediate compound (21)

To a solution of 19 (169 mg, 1.0 mmol) in dioxane (20 mL) and water (10mL) is added 4-iodobutyric acid (214 mg, 1.0 mmol). The resultingsolution is stirred for 24 hours. During this period of time, the pH ofthe solution is kept at 7-8 by adding 0.5 N NaOH solution. The solventsare removed under reduced pressure. The residue is purified using columnchromatography on silica, yielding compound 20.

To a solution of 20 (179 mg, 0.7 mmol) in dioxane (6 mL) and water (3mL) is added 1N NaOH (2.1 mL) at 0° C. To the resulting solution isadded di-tert-butyl dicarbonate (336 mg, 1.54 mmol) over the course of30 minutes. The mixture is stirred at room temperature for 12 hours.Dioxane is removed under reduced pressure. To the resulting watersolution is added ethyl acetate. The pH of the solution is adjusted toabout pH 3 by the addition of 0.2 N HCl solution at 0° C. The organiclayer is separated, washed with water (twice), dried over anhydrousMgSO₄, filtered and concentrated in vacuo. The residue is purified byusing column chromatography on silica, yielding intermediate compound21.

EXAMPLE 12 Synthesis of intermediate compound (24)

To a solution of 22 (169 mg, 1.0 mmol) in dioxane (20 mL) and water (10mL) is added 4-iodobutyric acid (214 mg, 1.0 mmol). The resultingsolution is stirred for 24 hours. During this period of time, the pH ofthe solution is kept at 7-8 by adding 0.5 N NaOH solution. The solventsare removed under reduced pressure. The residue is purified using columnchromatography on silica, yielding compound 23.

To a solution of 23 (179 mg, 0.7 mmol) in dioxane (6 mL) and water (3mL) is added 1N NaOH (1.4 mL) at 0° C. To the resulting solution isadded di-tert-butyl dicarbonate (168 mg, 0.77 mmol) over the course of30 minutes. The mixture is stirred at room temperature for 12 hours. ThepH of the solution is adjusted to about 4-5 by addition of 0.2 N HClsolution at 0° C. The solution is concentrated in vacuo. The residue ispurified by using column chromatography on silica, yielding intermediatecompound 24.

EXAMPLE 13 Synthesis of intermediate compound (27)

A mixture of 25 (205 mg, 1.00 mmol), 2-methylpropene (84 mg, 1.50 mmol),and concentrated H₂SO₄ in CH₂Cl₂ (20 mL) is stirred at room temperatureovernight. The solution is washed with saturated NaHCO₃ in aqueoussolution (2 times) and brine (2 times) and dried over anhydrous MgSO₄,filtered, and concentrated in vacuo. The residue is purified usingcolumn chromatography on silica, yielding compound 26.

To a mixture of 1-adamantanamine hydrochloride 26 (209 mg, 0.8 mmol) andN,N-diisopropylethylamine (310 mg, 2.4 mmol) in methylene chloride (20mL) is added 4-iodobutyric acid (171 mg, 0.8 mmol). The resultingsolution is stirred at room temperature overnight. The solution isconcentrated in vacuo. The residue is purified using columnchromatography on silica, yielding intermediate compound 27.

Synthesis of other Compounds

The compounds listed below can be synthesized according to theprocedures described above.

For the introduction of Dop1, Dop2, Dop3 or Dop4 residue(s) intopeptides, Dop1-OH, Dop2-OH, Dop3-OH or Dop4-OH (WO 02/100888 A1) wasused during the syntheses, respectively.

For the synthesis of the Dop5 containing peptides,Fmoc-Dopa(acetonide)-OH (Novabiochem, San Diego, Calif.) was used.

For the Dop6 residue in peptides, compound 11 is used during thesynthesis.

For the Dop7 residue in peptides, compound 21 is used during thesynthesis.

For the Dop8 residue in peptides, compound 14 is used during thesynthesis.

For the Dop9 residue in peptides, compound 24 is used during thesynthesis.

For the Dop10 residue in peptides, compound 3 is used during thesynthesis.

For the Dop11 residue in peptides, compound 6 is used during thesynthesis.

For the Dop12 residue in peptides, compound 27 is used during thesynthesis.

For the Dop13 residue in peptides, compound 18 is used during thesynthesis.

Table 1 lists somatostatin-dopamine chimeric analogs likely to havesomatostatin and dopamine activity in vitro or in vivo.

Table 1

-   -   Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Lys(Ac)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Ac)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop7-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop8-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop9-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop10-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop11-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop12-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop13-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop7-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop8-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop9-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop10-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop11-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop12-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop13-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop6-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop7-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop8-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop9-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop10-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop11-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop12-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop13-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop6-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop7-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop8-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop9-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop10-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop11-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop12-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop13-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop6-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop7-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop8-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop9-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop10-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop11-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop12-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop13-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop5-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop6-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop7-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop8-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop9-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop10-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop11-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop12-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop13-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop6-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop7-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop8-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop9-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop10-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop11-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop12-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop13-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop5-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop6-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop7-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop8-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop9-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop10-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop11-cyclo[Cys-Tyr-DTip-Lys-Thr-Cys]-2Nal-NH₂    -   Dop12-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop13-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop1-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop3-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop4-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop3-DPhe-cyclo[Cys-3Tyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop4-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop6-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop7-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop8-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop9-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop10-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop11-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop12-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop13-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop3-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop4-cyclo[Cys-3Tyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop6-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop7-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop8-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop9-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop10-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop11-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop12-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop13-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop3-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop3-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop5-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop6-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop7-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop8-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop9-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop10-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop11-Caeg-cyclo[DCys-3Pal-DTip-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop12-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop13-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop3-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop1-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop3-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop5-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop6-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop7-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop8-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop9-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop10-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop11-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop12-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop13-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-SerBzl)-Tyr-NH₂    -   Dop5-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop6-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop7-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop8-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop9-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop10-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop11-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop12-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop13-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop5-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop6-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop7-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop8-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop9-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop10-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop11-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop12-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop13-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop6-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop7-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop8-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop9-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop10-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop11-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop12-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop13-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop1-Lys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Thr-Cys]-2Nal-NH₂    -   Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop1-Lys(Dop1)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop1-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop1-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop1-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop1-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop2-Lys(Dop2)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-DLys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-DLys(Dop3)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-DLys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-DLys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-DLys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Abu-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop3-Lys(Dop3)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Trp-NH₂    -   Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo        [Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NE2    -   Dop4-Lys(Dop4)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-DLys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-DLys(Dop4)-Aepa-DPhe-cyclo        [Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-DLys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-DLys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-DLys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop4-Lys(Dop4)-cyclo[Cys-Phe-DTip-Lys-Thr-Cys]-Thr-ol    -   Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Tip-NH₂    -   Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-N—H2    -   Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTip-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop5-Lys(Dop5)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Tip-NH₂    -   Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-DLys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-DLys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-DLys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-DLys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop6-Lys(Dop6)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Trp-NH₂    -   Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop7-DLys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop7-DLys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop7-Lys(Dop7)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop7-Lys(Dop7)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop8-DLys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop8-DLys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop8-Lys(Dop8)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop8-Lys(Dop8)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop9-DLys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop9-DLys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop9-Lys(Dop9)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop9-Lys(Dop9)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop10-DLys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop10-DLys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop10-Lys(Dop10)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop10-Lys(Dop10)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop11-DLys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop11-DLys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop11-Lys(Dop11)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH.    -   Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop11-Lys(Dop11)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop12-DLys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop12-DLys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop12-Lys(Dop12)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop12-Lys(Dop12)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop13-DLys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop13-DLys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop13-Lys(Dop13)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂    -   Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop13-Lys(Dop13)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol    -   Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂    -   Dop1-Lys(Dop1)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-Lys(Dop1)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop1-DLys(Dop1)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-DLys(Dop1)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop1-Lys(Dop1)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-Lys(Dop1)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop1-DLys(Dop1)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-DLys(Dop1)-Lys-Caeg-cyclo[DCys-Phe-DTip-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop1-Lys(Dop1)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-Lys(Dop1)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop1-DLys(Dop1)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-DLys(Dop1)-Aepa-Caeg-cyclo[DCys-Phe-DTp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop1-Lys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-Lys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop1-DLys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop1-DLys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-Lys(Dop2)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-Lys(Dop2)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-DLys(Dop2)-Caeg-cyclo[DCys-3Pal-DTip-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-DLys(Dop2)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-Lys(Dop2)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-Lys(Dop2)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-DLys(Dop2)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-DLys(Dop2)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-Lys(Dop2)-Aepa-Caeg-cyclo[DCys-3Pal-DTip-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-Lys(Dop2)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-DLys(Dop2)-Aepa-Caeg-cyclo[DCys-3Pal-DTp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-DLys(Dop2)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-Lys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-Lys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop2-DLys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop2-DLys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop3-Lys(Dop3)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop3-Lys(Dop3)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop3-Lys(Dop3)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop3-Lys(Dop3)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop3-Lys(Dop3)-Aepa-Caeg-cyclo[DCys-3Pal-DTip-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop3-Lys(Dop3)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH-Dop3-DLys(Dop3)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH2    -   Dop3-DLys(Dop3)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop3-DLys(Dop3)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop3-DLys(Dop3)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop3-DLys(Dop3)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop3-DLys(Dop3)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-Lys(Dop4)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-Lys(Dop4)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-Lys(Dop4)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-Lys(Dop4)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-Lys(Dop4)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-Lys(Dop4)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-Lys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-Lys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-DLys(Dop4)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-DLys(Dop4)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-DLys(Dop4)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-DLys(Dop4)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-DLys(Dop4)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-DLys(Dop4)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop4-DLys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop4-DLys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop5-Lys(Dop5)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop5-Lys(Dop5)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop5-DLys(Dop5)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop5-DLys(Dop5)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop5-Lys(Dop5)-Lys-Caeg-cyclo[DCys-3Pal-DTp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop5-Lys(Dop5)-Lys-Caeg-cyclo[DCys-Phe-DTip-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop5-DLys(Dop5)-Lys-Caeg-cyclo[DCys-3Pal-DTp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop5-DLys(Dop)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop6-Lys(Dop6)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop6-Lys(Dop6)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop6-DLys(Dop6)-Caeg-cyclo[DCys-3Pal-DTp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop6-DLys(Dop6)-Caeg-cyclo[DCys-Phe-DTip-Lys-DCys]-Ser(Bzl)-Tyr-NH,    -   Dop6-Lys(Dop6)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop6-Lys(Dop6)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop6-DLys(Dop6)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop6-DLys(Dop6)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop7-Lys(Dop7)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop7-Lys(Dop7)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop7-Lys(Dop7)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop7-Lys(Dop7)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop8-Lys(Dop8)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop8-Lys(Dop8)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop8-Lys(Dop8)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop8-Lys(Dop8)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop9-Lys(Dop9)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop9-Lys(Dop9)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop9-Lys(Dop9)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop9-Lys(Dop9)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop10-Lys(Dop10)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop10-Lys(Dop10)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop10-Lys(Dop10)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop10-Lys(Dop10)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop11-Lys(Dop11)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop11-Lys(Dop11)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop11-Lys(Dop11)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop11-Lys(Dop11)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop12-Lys(Dop12)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop12-Lys(Dop12)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop12-Lys(Dop12)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop12-Lys(Dop12)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop13-Lys(Dop13)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop13-Lys(Dop13)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop13-Lys(Dop13)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂    -   Dop13-Lys(Dop13)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂    -   Dop1-Lys(Dop1)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop1-DLys(Dop1)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NE₂    -   Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop5-DLys(Dop5)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop6-DLys(Dop6)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop6-DLys(Dop6)-DPhe-cyclo[Cys-Phe-(N-Me)DTip-Lys-Thr-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop6-DLys(Dop6)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop7-Lys(Dop7)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop7-Lys(Dop7)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop8-Lys(Dop8)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop9-Lys(Dop9)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop10-Lys(Dop10)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop11-Lys(Dop11)-cyclo[Cys-Phe-Phe-DTtp-Lys-Thr-Phe-Cys]-NH₂    -   Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop12-Lys(Dop12)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop13-Lys(Dop13)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂    -   Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Phe-(N-Me)DTip-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-DPhe-cyclo[Cys-3ITyr(Dop1)-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop1)-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTip-Lys-Val-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTip-Lys-Val-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂        Example 1    -   Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop3-Lys(Dop3)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop4-Lys(Dop4)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTip-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTip-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTip-Lys-Val-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop7-Lys(Dop7)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop8-Lys(Dop8)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop9-Lys(Dop9)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop10-Lys(Dop10)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop11-Lys(Dop11)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop12-Lys(Dop12)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop13-Lys(Dop13)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop6-Lys(Dop6)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop7-Lys(Dop7)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop8-Lys(Dop8)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop9-Lys(Dop9)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop10-Lys(Dop10)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop11-Lys(Dop11)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop12-Lys(Dop12)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂    -   Dop13-Lys(Dop13)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂

Some of the compounds of the instant invention have at least oneasymmetric center. Additional asymmetric centers may be present in themolecule depending upon the nature of the various substituents of themolecule. Each such asymmetric center will produce two optical isomersand it is intended that all such optical isomers, as separated, pure orpartially purified optical isomers, racemic mixtures or diastereomericmixtures thereof, are included within the scope of the instantinvention.

The compounds of the instant invention generally can be provided in theform of their pharmaceutically acceptable acid addition salts, such asthe salts derived from using inorganic and organic acids. Examples ofsuch acids are hydrochloric, nitric, sulfuric, phosphoric, formic,acetic, trifluoroacetic, propionic, maleic, succinic, D-tartaric,L-tartaric, malonic, methane sulfonic and the like. In addition, certaincompounds containing an acidic function such as a carboxy can beisolated in the form of their inorganic salt in which the counter-ioncan be selected from sodium, potassium, lithium, calcium, magnesium andthe like, as well as from organic bases.

The pharmaceutically acceptable salts can be formed by taking about 1equivalent of a compound of the invention and contacting it with about 1equivalent or more of the appropriate corresponding acid of the saltwhich is desired. Work-up and isolation of the resulting salt iswell-known to those of ordinary skill in the art.

The compounds of this invention can be administered by oral, parenteral(e.g., intramuscular, intraperitoneal, intravenous or subcutaneousinjection, or implant), nasal, vaginal, rectal, sublingual or topicalroutes of administration and can be formulated with pharmaceuticallyacceptable carriers to provide dosage forms appropriate for each routeof administration. Accordingly, the present invention featurespharmaceutical compositions comprising, as an active ingredient, atleast one compound of the invention in association with apharmaceutically acceptable carrier.

Solid dosage forms for oral administration include capsules, tablets,pills, powders and granules. In such solid dosage forms, the activecompound is admixed with at least one inert pharmaceutically acceptablecarrier such as sucrose, lactose, or starch. Such dosage forms can alsocomprise, as is normal practice, additional substances other than suchinert diluents, e.g., lubricating agents such as magnesium stearate. Inthe case of capsules, tablets and pills, the dosage forms may alsocomprise buffering agents. Tablets and pills can additionally beprepared with enteric coatings.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups, the elixirscontaining inert diluents commonly used in the art, such as water.Besides such inert diluents, compositions can also include adjuvants,such as wetting agents, emulsifying and suspending agents, andsweetening, flavoring and perfuming agents.

Preparations according to this invention for parenteral administrationinclude sterile aqueous or non-aqueous solutions, suspensions, oremulsions. Examples of non-aqueous solvents or vehicles are propyleneglycol, polyethylene glycol, vegetable oils, such as olive oil and cornoil, gelatin, and injectable organic esters such as ethyl oleate. Suchdosage forms may also contain adjuvants such as preserving, wetting,emulsifying, and dispersing agents. They may be sterilized by, forexample, filtration through a bacteria-retaining filter, byincorporating sterilizing agents into the compositions, by irradiatingthe compositions, or by heating the compositions. They can also bemanufactured in the form of sterile solid compositions which can bedissolved in sterile water, or some other sterile injectable mediumimmediately before use.

Compositions for rectal or vaginal administration are preferablysuppositories which may contain, in addition to the active substance,excipients such as coca butter or a suppository wax.

Compositions for nasal or sublingual administration are also preparedwith standard excipients well known in the art.

In general, an effective dose of an active ingredient in thecompositions of this invention may be varied; however, it is necessarythat the amount of the active ingredient be such that a suitable dosageform is obtained. The selected dosage depends upon the desiredtherapeutic effect, on the route of administration, and on the durationof the treatment, all of which are within the realm of knowledge of oneof ordinary skill in the art. Generally, dosage levels of between 0.0001to 100 mg/kg of body weight daily are administered to humans and otheranimals, e.g., mammals.

Preferred dosage ranges are from 0.01 to 10.0 mg/kg of body weight. Suchdosages may be administered, for example, daily as a single dose ordivided into multiple doses.

Somatostatin Receptor Specificity and Selectivity Assay

Specificity and selectivity of the somatostatin analogues used tosynthesize the somatostatin-dopamine chimers was determined by aradioligand binding assay on CHO-K1 cells stably transfected with eachof the SSTR subtypes, as follows. Somatostatin analogs are alsodescribed in U.S. Patent Application Publication No. 02210006790. Thecomplete coding sequences of genomic fragments of the SSTR 1 (e.g.,Genbank accession No. M81829), SSTR 2 (e.g., Genbank accession No.M81830), SSTR 3 (e.g., Genbank accession No. L07062), and SSTR 4 (e.g.,Genbank accession No. AL049651) genes and a cDNA clone for SSTR 5 (e.g.,Genbank accession No. D16827) was subcloned into the mammalianexpression vector pCMV (Life Technologies, Milano, Italy). Other SSTRsequences are known to the skilled artisan. Clonal cell lines stablyexpressing SSTR's 1-5 were obtained by transfection into CHO-K1 cells(ATCC, Manassas, Va., USA) using the calcium phosphate co-precipitationmethod (Davis L, et al., 1994 In: Basic methods in Molecular Biology,2nd edition, Appleton & Lange, Norwalk, Conn., USA: 611-646). Theplasmid pRSV-neo (ATCC) was included as a selectable marker. Clonal celllines were selected in RPMI 1640 media containing 0.5 mg/ml of G418(Life Technologies, Milano, Italy), ring cloned, and expanded intoculture.

Membranes for in vitro receptor binding assays were obtained byhomogenizing the CHO-K1 cells expressing the SSTR's subtypes in ice-cold50 mM Tris-HCl and centrifuging twice at 39000 g (10 min), with anintermediate resuspension in fresh buffer. The final pellets wereresuspended in 10 mM Tris-HCl for assay.

For the SSTR 1, 3, 4, and 5 assays, aliquots of the membranepreparations were incubated 90 minutes at 25° C. with 0.05 nM[¹²⁵I-Tyr11]SS-14 in 50 mM HEPES (pH 7.4) containing 10 mg/ml bovineserum albumin (BSA), 5 mM MgCl₂, 200 KIU/ml Trasylol, 0.02 mg/mlbacitracin, and 0.02 mg/ml phenylmethylsuphonyl fluoride. The finalassay volume was 0.3 ml.

For the SSTR 2 assay, 0.05 nM [¹²⁵I]MK-678 was employed as theradioligand and the incubation time was 90 minutes at 25° C. Theincubations were terminated by rapid filtration through GF/C glassmicrofibre filters (Whatman Co.) (pre-soaked in 0.3% polyethylenimine)using a BRANDEL filtration manifold. Each tube and filter was washedthree times with 5 ml aliquots of ice-cold buffer. Specific binding wasdefined as the total radioligand bound minus that bound in the presenceof 1000 nM SS-14 for SSTR 1, 3, 4, and 5, or 1000 nM MK-678 for SSTR2.

Dopamine Receptor Specificity and Selectivity Assay

Specificity and selectivity for the dopamine-2 receptor of the dopamineanalogues used to synthesize the somatostatin-dopamine chimers may bedetermined by a radioligand binding assay as follows.

Crude membranes were prepared by homogenization of frozen rat corpusstriatum (Zivic Laboratories, Pittsburgh, Pa.) in 20 ml of ice-cold 50mM Tris-HCl with a BRINKMAN POLYTRON cell disrupter (setting 6, 15 sec).Buffer was added to obtain a final volume of 40 ml, and the homogenatewas centrifuged in a SORVAL SS-34 rotor at 39,000 g for 10 minutes at0-4° C. The resulting supernatant was decanted and discarded. The pelletwas rehomogenized in ice-cold buffer, pre-incubated at 37° C. for 10min, diluted, and centrifuged as before. The final pellet wasresuspended in buffer and held on ice for the receptor binding assay.

For assay, aliquots of the washed membrane preparations and testcompounds were incubated for 15 minutes (37° C.) with 0.25 nM[³HI]spiperone (16.5 Ci.mmol, New England Nuclear, Boston, Mass.) in 50mM Tris HCl, 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂. The finalassay volume was 1.0 ml. The incubations were terminated by rapidfiltration through GF/B glass fibre filters using a Brandel filtrationmanifold. Each tube and filter was then washed three times with 5-mlaliquots of ice-cold buffer. Specific binding was defined as the totalradioligand bound minus that bound in the presence of 1000 nM (+)butaclamol.

Inhibition of cAMP Intracellular Production

The agonist activity of a somatostatin test compound is determined bythe following assay.

CHO-K1 cells expressing human somatostatin (SRIF-14) subtype receptorsare seeded in 24-well tissue culture plates in RPMI 1640 media with 10%fetal calf serum (FCS).

Cells at 10⁵ cells/well are washed 2 times by 0.5 ml RPMI 1640 media.Hank's balanced salt solution supplemented with 0.5 mM3-isobutyl-1-methylxanthine (“IBMX”), and the cells are incubated for 30minutes at 37° C. Cyclic AMP production is stimulated by the addition of10 μM forskolin (“FSK”) (Sigma Chemical Co., St. Louis, Mo.) for 30minutes at 37° C.

The agonist effect of a compound is measured by the addition of the testcompound (10⁻¹⁰ M to 10⁻⁶ M) for five minutes prior to the addition ofFSK (10 μM). The reaction is terminated by the addition of 500 μl ofice-cold absolute alcohol, and the supernatant is transferred to a 12×75mm glass tube for cAMP determination. cAMP is measured usingradioimmunoassay kit (Perkin-Elmer, Boston, Mass.).

Other Embodiments

Various modifications and variations of the described method and systemof the invention will be apparent to those skilled in the art withoutdeparting from the scope and spirit of the invention. Although theinvention has been described in connection with specific desiredembodiments, it should be understood that the invention as claimedshould not be unduly limited to such specific embodiments. Indeed,various modifications of the described modes for carrying out theinvention that are obvious to those skilled in the fields of medicine,immunology, pharmacology, endocrinology, or related fields are intendedto be within the scope of the invention.

All publications mentioned in this specification, includingPCT/US02/17859, are herein incorporated by reference to the same extentas if the disclosure of each independent publication was explicitlyprovided herein.

1. A chimeric analog comprising (1) at least one moiety which binds toone or more somatostatin receptor(s) and (2) at least one moiety whichbinds to one or more dopamine receptor(s), or a pharmaceuticallyacceptable salt thereof.
 2. The chimeric analog of claim 1, wherein saidchimeric analog comprises formula (I),

wherein: X is H, Cl, Br, I, F, —CN, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl,C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀heteroalkyl, substituted C₂₋₁₀ alkenyl, or substituted C₂₋₁₀ alkynyl; R1is H, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl, substitutedC₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkynyl, or —CN; R2 and R3, each is,independently, H or absent, provided that when R2 and R3 are absent adouble bond is present between the carbon atoms to which they areattached; R4 is H, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀alkynyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl,substituted C₂₋₁₀ alkenyl, or substituted C₂₋₁₀ alkynyl; Y is —O—,—C(O)—, —S—, —S—(CH₂)_(s)—C(O)—, —S(O)—, —S(O)₂—, —SC(O)—, —OC(O)—,—N(R5)—C(O)—, or —N(R6)—; L is —(CH₂)_(p)—C(O)—, when Y is —S—, —S(O)—,—S(O)₂—, —O— or —N(R6)—; or L is —C(O)—(CR7R8)_(q)—C(O)—, when Y is—N(R6)—, —O—, or —S—; or L is (amino acid)_(t), when Y is —C(O)—,SC(O)—, —OC(O)—, —S—(CH₂)_(s)—C(O)—, or —N(R5)—C(O)—; W is —CR9,R10- R5and R6 each is, independently, H, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl;C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl,aryl, alkylaryl, or substituted alkylaryl; R7, R8, R9, and R10 each is,independently, H, F, Cl, Br, I, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl;C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl,aryl, alkylaryl, or substituted akylaryl; or R7 and R8 can, optionally,join together to form a ring system; or R9 and R10 can, optionally, jointogether to form a ring system; i is 1-10, provided that when i is 1,then R1 is not H, C₁₋₄ alkyl, allyl, alkenyl or —CN, R4 is not H or—CH₃, R5, R6, R7 and R8 each is, independently, not H or C₁₋₅ alkyl, Lis not -(Doc)t-, X is not H, Cl, Br, I, F, —CN, or C₁₋₅ alkyl, or R9 andR10 each is, independently, not H; m is 0 or 1; n is 0-10; p is 1-10; qis 1-5; s is 1-10; t is 1-10; Z is a ligand of at least one somatostatinreceptor; or a pharmaceutically acceptable salt thereof; and whereineach moiety depicted between the brackets is, independently for eachoccurrence, attached to an N-terminal or an internal amine group,carboxylic acid group, or hydroxyl group of Z.
 3. The chimeric analog ofclaim 1, wherein said chimeric analog comprises formula (II),

wherein: X is H, Cl, Br, I, F, —CN, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl,C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀heteroalkyl, substituted C₂₋₀ alkenyl, or substituted C₂₋₁₀ alkynyl; R1is H, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl, substitutedC₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkynyl, or —CN; R2 and R3, each is,independently, H or absent, provided that when R2 and R3 are absent adouble bond is present between the carbon atoms to which they areattached; R4 is H, C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀alkynyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl,substituted C₂₋₁₀ alkenyl, or substituted C₂₋₁₀ alkynyl; R5 is H, C₁₋₁₀alkyl, C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substitutedC₁₋₁₀ alkyl, substituted C₁₋₁₀ heteroalkyl, substituted C₂₋₁₀ alkenyl,substituted C₂₋₁₀ alkynyl, or a group of the formula of—(CH₂)_(r)N(R11,R12); Y is —O—, —C(O)—, —S—, —SC(O)—, —OC(O)—,—N(R6)—C(O)—, —N(R7)—, or —N(R8)—(CH₂)_(s)—C(O)—; L is —(CH₂)_(p)—C(O)—,when Y is —S—, —O— or —N(R7)—; or L is —C(O)—(CR9R10)_(q)—C(O)—, when Yis —N(R7)—, —O—, or —S—; or L is (amino acid)_(t), when Y is —C(O)—,SC(O)—, —OC(O)—, —N(R8)—(CH₂)_(s)—C(O)—, or —N(R6)—C(O)—; W is—CR9,R10-; R6, R7, and R8 each is, independently, H, C₁₋₁₀ alkyl,substituted C₁₋₁₀ alkyl, C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; R9,and R10 each is, independently, H, Cl, Br, I, F, C₁₋₁₀ alkyl,substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; orR9 and R10 can, optionally, join together to form a ring system; R11,and R12 each is, independently, H, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl;C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl,aryl, alkylaryl, or substituted akylaryl; i is 1-10, provided that wheni is 1, then R1 is not H, C₁₋₄ alkyl, allyl, alkenyl or —CN, R4 is not Hor —CH₃, R5 is not C₁₋₅ alkyl group or a group of the formula of—(CH₂)_(r)N(CH₃)_(v), R6, R7, R8, R9 and R10 each is, independently, notH or C₁₋₅ alkyl, L is not -(Doc)t-, or X is not H, Cl, Br, I, F, —CN, orC₁₋₅ alkyl; m is 0 or 1; n is 2-10; p is 1-10; q is 1-5; r is 1-8; s is1-10; t is 1-10; v is 2-4; Z is a ligand of at least one somatostatinreceptor; or a pharmaceutically acceptable salt thereof; and whereineach moiety depicted between the brackets is, independently for eachoccurrence, attached to an N-terminal or an internal amine group,carboxylic acid or hydroxyl group of Z.
 4. The chimeric analog of claim1, wherein said chimeric analog comprises formula (III),

wherein: R2 is H, —N(R11)N(R12,R13), —N(R6R7), or —COOH; R4 and R5 eachis, independently, H, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substitutedC₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl, aryl,alkylaryl, substituted akylaryl or R8-C(O)—; W is —CR9R10— or—(CH2)_(q)—NH—(CH2)_(r)—; R1, R6, R7, R8, R11, R12 and R13 each is,independently, H, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substitutedC₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl, aryl,alkylaryl, or substituted akylaryl; R9 and R10 each is, independently,H, —OH, —CN, —NO₂, F, Cl, Br, I, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl;C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl,akylaryl, substituted alkylaryl, or aryl; X is C₁₋₁₀ alkyl, substitutedC₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀alkynyl, akylaryl, substituted alkylaryl, aryl, or acyl; Q is C or N;provided that when Q is N, then R2 is absent; i is 1-10; n is 1-6; q is1-6; r is 1-8; Z is a ligand of at least one somatostatin receptor; or apharmaceutically acceptable salt thereof; and wherein each moietydepicted between the brackets is, independently for each occurrence,attached to an N-termninal or an internal amine group or hydroxyl groupof Z.
 5. The chimeric analog of claim 1, wherein said chimeric analogcomprises formula (IV),

wherein: R1 and R2 each is, independently, H, C₁₋₁₀ alkyl, substitutedC₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀alkynyl, aryl, alkylaryl, or substituted akylaryl; R3, R4, R5, R6 and R7each is, independently, H, —OH, —CN, —NO₂, F, Cl, Br, I, C₁₋₁₀ alkyl,substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; Wis —CR4R5-; Y is —CR6R7)_(m)—C(O)— or acyl; m is 0-10; n is 1-6; Z is aligand of at least one somatostatin receptor; or a pharmaceuticallyacceptable salt thereof; and wherein each moiety depicted between thebrackets is, independently for each occurrence, attached to anN-terminal or an internal amine group or hydroxyl group of Z.
 6. Thechimeric analog of claim 1, wherein said chimeric analog comprisesformula (V),

wherein: P is —N(R3R4) or H; X is N or S; W is —CR5R6-; Y is—CR7R8)_(m)—C(O)—; R1, R3 and R4 each is, independently, H, C₁₋₁₀ alkyl,substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; R2,R5, R6, R7 and R8 each is, independently, H, —OH, —CN, —NO₂, F, Cl, Br,I, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substitutedC₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀alkynyl, substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substitutedakylaryl; i is 1-10; m is 0-10; n is 0-6; Z is a ligand of at least onesomatostatin receptor; or a pharmaceutically acceptable salt thereof;and wherein each moiety depicted between the brackets is, independentlyfor each occurrence, attached to an N-terminal or an internal aminegroup or hydroxyl group of Z.
 7. The chimeric analog of claim 1, whereinsaid chimeric analog comprises formula (VI),

wherein: Y is —(CR2R3)_(m)—C(O)— or acyl; R1 is H, C₁₋₁₀ alkyl,substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; R2and R3 each is, independently, H, —OH, —CN, —NO₂, F, Cl, Br, I, C₁₋₁₀alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; iis 1-10; m is 0-10; Z is a ligand of at least one somatostatin receptor;or a pharmaceutically acceptable salt thereof, and wherein each moietydepicted between the brackets is, independently for each occurrence,attached to an N-terminal or an internal amine group or hydroxyl groupof Z.
 8. The chimeric analog of claim 1, wherein said chimeric analogcomprises formula (VII),

wherein: P is —N(R3R4) or H; L is —CR5R6)_(m)—C(O)— or acyl; Y is C₁₋₁₀alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, substituted akylaryl, orabsent; R1, R2, R5 and R6 each is, independently, H, —OH, —CN, —NO₂, F,Cl, Br, I, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl,substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl,C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, orsubstituted akylaryl; R3 and R4 each is, independently, H, C₁₋₁₀ alkyl,substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; iis 1-10; m is 0-10; Z is a ligand of at least one somatostatin receptor;or a pharmaceutically acceptable salt thereof; and wherein each moietydepicted between the brackets is, independently for each occurrence,attached to an N-terminal or an internal amine group or hydroxyl groupof Z.
 9. The chimeric analog of claim 1, wherein said chimeric analogcomprises formula (VIII),

wherein: X and Y each is, independently, —OH, —OR4 or R5-C(O)—O—; L is—(CR3R4)_(m)—C(O)— or acyl; R1,R2, R3 and R4 each is, independently, H,—OH, F, Cl, Br, I, —CN, NO₂, C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl, substitutedC₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl, aryl,alkylaryl, or substituted akylaryl; or R2 and R3 can, optionally, jointogether to form a ring system; R5 is H, C₁₋₁₀ alkyl, substituted C₁₋₁₀alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀ alkenyl,substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀ alkynyl,aryl, alkylaryl, or substituted akylaryl; i is 1-10; m is 0-10; Z is aligand of at least one somatostatin receptor; or a pharmaceuticallyacceptable salt thereof; and wherein each moiety depicted between thebrackets is, independently for each occurrence, attached to anN-terminal or an internal amine group or hydroxyl group of Z.
 10. Thechimeric analog of claim 1, wherein said chimeric analog comprisesformula (IX),

wherein: X and Y each is, independently, —OH, —OR4 or R7-C(O)—; Q is—CR5R6)_(m)—C(O)— or acyl; R1, R2, R3, R4, R5 and R6 each is,independently, H, —OH, F, Cl, Br, I, —CN, NO₂, C₁₋₁₀ alkyl, substitutedC₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀ heteroalkyl, C₂₋₁₀alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, substituted C₂₋₁₀alkynyl, aryl, alkylaryl, or substituted akylaryl; or R1 and R2 can,optionally, join together to form a ring system; or R3 and R4 can,optionally, join together to form a ring system; R7 is H, C₁₋₁₀ alkyl,substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; iis 1-10; m is 0-10; Z is a ligand of at least one somatostatin receptor;or a pharmaceutically acceptable salt thereof, and wherein each moietydepicted between the brackets is, independently for each occurrence,attached to an N-terminal or an internal amine group or hydroxyl groupof Z.
 11. The chimeric analog of claim 1, wherein said chimeric analogcomprises formula (X),

wherein: Y is —(CR8R9)_(m)—C(O)— or acyl; R1, R2, R3, R4, R5, R6, R7, R8and R9 each is, independently, H, —OH, F, Cl, Br, I, —CN, NO₂, C₁₋₁₀alkyl, substituted C₁₋₁₀ alkyl; C₁₋₁₀ heteroalkyl, substituted C₁₋₁₀heteroalkyl, C₂₋₁₀ alkenyl, substituted C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,substituted C₂₋₁₀ alkynyl, aryl, alkylaryl, or substituted akylaryl; iis 1-10; m is 0-10; Z is a ligand of at least one somatostatin receptor;or a pharmaceutically acceptable salt thereof; and wherein each moietydepicted between the brackets is, independently for each occurrence,attached to an N-terminal or an internal amine group or hydroxyl groupof Z.
 12. The chimeric analog of claim 1, wherein said chimeric analogcomprises a compound according to the formula of:Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Ac)-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Ac)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Tyr-DTip-Lys-Abu-Cys]-Thr-NH₂,Dop6-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop7-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop8-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop9-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop10-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop11-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop12-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop13-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop6-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop7-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop8-cyclo[Cys-Tyr-DTip-Lys-Abu-Cys]-Thr-NH₂,Dop9-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop10-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop11-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop12-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop13-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop6-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂Dop7-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop8-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop9-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop10-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop11-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop12-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop13-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop6-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop7-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop8-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop9-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop10-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop11-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop12-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop13-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop6-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop7-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop8-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop9-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop10-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop11-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop12-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop13-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop5-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop6-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop7-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop8-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop9-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop10-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop11-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop12-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop13-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop6-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop7-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop8-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop9-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop10-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop11-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop12-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop13-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop5-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop6-cyclo[Cys-Tyr-DTip-Lys-Thr-Cys]-2Nal-NH₂,Dop7-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop8-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop9-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop10-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop11-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop12-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop13-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop1-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-Aepa-DPhe-cyclo [Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Aepa-DPhe-cyclo [Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop4-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop6-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop7-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop8-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop9-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop10-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop11-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop12-DPhe-cyclo[Cys-3ITyr-DTip-Lys-Thr-Cys]-Thr-NH₂,Dop13-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop4-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop6-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop7-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop8-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop9-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop10-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop11-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop12-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop13-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop3-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop4-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop3-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop4-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop5-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop6-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop7-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop8-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop9-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop10-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop11-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop12-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop13-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop3-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop4-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop3-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop4-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop5-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop6-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop7-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop8-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop9-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop10-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop12-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop13-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-SerBzl)-Tyr-NH₂,Dop5-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop6-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop7-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop8-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop9-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop10-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop11-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop12-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop13-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop5-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop6-DPhe-cyclo[Cys-Phe-(N-Me)DTip-Lys-Thr-Cys]-Thr-NH₂,Dop7-DPhe-cyclo[Cys-Phe-(N-Me)DTip-Lys-Thr-Cys]-Thr-NH₂,Dop8-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop9-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop10-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop11-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop12-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop13-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop6-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop7-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop8-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop9-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop10-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop11-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop12-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop13-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop1-Lys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop1-Lys(Dop1)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop1-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop1-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop1-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop1-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop2-Lys(Dop2)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Trp-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-DLys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-DLys(Dop3)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NE₂,Dop3-DLys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-DLys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-DLys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop3-Lys(Dop3)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Trp-NH₂,Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DLys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DLys(Dop4)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DLys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DLys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DLys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-DPhe-cyclo [Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop4-Lys(Dop4)-DPhe-cyclo [Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop4-Lys(Dop4)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo [Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop5-Lys(Dop5)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Trp-NH₂,Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop6-DLys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop6-DLys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop6-DLys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop6-DLys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop6-Lys(Dop6)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Tip-NH₂,Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Trp-NH₂,Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop7-Lys(Dop7)-DPhe-cyclo [Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop7-DLys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop7-DLys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop7-Lys(Dop7)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop7-Lys(Dop7)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Tip-NH₂,Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop8-DLys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop8-DLys(Dop8)-cyclo[Cys-Tyr-DTip-Lys-Abu-Cys]-Thr-NH₂,Dop8-Lys(Dop8)-D2Nal-cyclo[Cys-Tyr-DTip-Lys-Val-Cys]-Thr-NH₂,Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop8-Lys(Dop8)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Tip-NH₂,Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop9-DLys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop9-DLys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop9-Lys(Dop9)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop9-Lys(Dop9)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Tip-NH₂,Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Tip-NH₂,Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop10-DLys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop10-DLys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop10-Lys(Dop10)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop10-Lys(Dop10)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop11-DLys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop11-DLys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop11-Lys(Dop11)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop11-Lys(Dop11)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop12-DLys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop12-DLys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop12-Lys(Dop12)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop12-Lys(Dop12)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop13-DLys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop13-DLys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop13-Lys(Dop13)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH₂,Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop13-Lys(Dop13)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH₂,Dop1-Lys(Dop1)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-Lys(Dop1)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-DLys(Dop1)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-DLys(Dop1)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-Lys(Dop1)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-Lys(Dop1)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-DLys(Dop1)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-DLys(Dop1)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-Lys(Dop1)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-Lys(Dop1)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-DLys(Dop1)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-DLys(Dop1)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-Lys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-Lys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-DLys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop1-DLys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-Lys(Dop2)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-Lys(Dop2)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-DLys(Dop2)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-DLys(Dop2)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-Lys(Dop2)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-Lys(Dop2)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-DLys(Dop2)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-DLys(Dop2)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-Lys(Dop2)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-Lys(Dop2)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-DLys(Dop2)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-DLys(Dop2)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-Lys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-Lys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop2-DLys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop2-DLys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop3-Lys(Dop3)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop3-Lys(Dop3)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop3-Lys(Dop3)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop3-Lys(Dop3)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop3-Lys(Dop3)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop3-Lys(Dop3)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop3-DLys(Dop3)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop3-DLys(Dop3)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop3-DLys(Dop3)-Lys-Caeg-cyclo[DCys-3Pal-DTip-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop3-DLys(Dop3)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop3-DLys(Dop3)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop3-DLys(Dop3)-Aepa-Caeg-cyclo[DCys-Phe-DTp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop4-Lys(Dop4)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop4-Lys(Dop4)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop4-Lys(Dop4)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂Dop4-Lys(Dop4)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂Dop4-Lys(Dop4)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂Dop4-Lys(Dop4)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂Dop4-Lys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop4-Lys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop4-DLys(Dop4)-Caeg-cyclo[DCys-3Pal-DTip-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop4-DLys(Dop4)-Caeg-cyclo[DCys-Phe-DTip-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop4-DLys(Dop4)-Lys-Caeg-cyclo[DCys-3Pal-DTip-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop4-DLys(Dop4)-Lys-Caeg-cyclo[DCys-Phe-DTip-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop4-DLys(Dop4)-Aepa-Caeg-cyclo[DCys-3Pal-DTip-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop4-DLys(Dop4)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop4-DLys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop4-DLys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop5-Lys(Dop5)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop5-Lys(Dop5)-Caeg-cyclo[DCys-Phe-DTp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop5-DLys(Dop)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop5-DLys(Dop5)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop5-Lys(Dop5)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop5-Lys(Dop5)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop5-DLys(Dop)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop5-DLys(Dop5)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop6-Lys(Dop6)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop6-Lys(Dop6)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop6-DLys(Dop6)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH.)Dop6-DLys(Dop6)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop6-Lys(Dop6)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop6-Lys(Dop6)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop6-DLys(Dop6)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop6-DLys(Dop6)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop7-Lys(Dop7)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop7-Lys(Dop7)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop7-Lys(Dop7)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop7-Lys(Dop7)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop8-Lys(Dop8)-Caeg-cyclo[DCys-3Pal-DTip-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop8-Lys(Dop8)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop8-Lys(Dop8)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop8-Lys(Dop8)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop9-Lys(Dop9)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop9-Lys(Dop9)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop9-Lys(Dop9)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop9-Lys(Dop9)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop10-Lys(Dop10)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop10-Lys(Dop10)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop10-Lys(Dop10)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop10-Lys(Dop10)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop11-Lys(Dop11)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop11-Lys(Dop11)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop11-Lys(Dop11)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop11-Lys(Dop11)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop12-Lys(Dop12)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop12-Lys(Dop12)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop12-Lys(Dop12)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop12-Lys(Dop12)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop13-Lys(Dop13)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop13-Lys(Dop13)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop13-Lys(Dop13)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,Dop13-Lys(Dop13)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,Dop1-Lys(Dop1)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop1-Lys(Dop)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop1-DLys(Dop1)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop2-DLys(Dop2)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂Dop5-Lys(Dop5)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo [Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop5-DLys(Dop5)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop6-DLys(Dop6)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop6-DLys(Dop6)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop6-DLys(Dop6)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop7-Lys(Dop7)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop7-Lys(Dop7)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop8-Lys(Dop8)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Phe-(N-Me)DTip-Lys-Thr-Cys]-Thr-NH₂,Dop9-Lys(Dop9)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Phe-(N-Me)DTip-Lys-Thr-Cys]-Thr-NH₂,Dop10-Lys(Dop10)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop11-Lys(Dop11)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop12-Lys(Dop12)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop13-Lys(Dop13)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,Dop13-Lys(Dop13)-DPhe-cyclo [Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-DPhe-cyclo[Cys-3ITyr(Dop1)-DTip-Lys-Val-Cys]-Thr-NH₂,Dop1-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop1)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-cyclo[Cys-3ITyr-DTip-Lys-Thr-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-DLys(Dop10)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-3Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTp-Lys-Val-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTtp-Lys-Val-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTip-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTip-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NIH₂,Dop2-Lys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTip-Lys-Val-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-Lys(Dop3)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop4-Lys(Dop4)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop7-Lys(Dop7)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop8-Lys(Dop8)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop9-Lys(Dop9)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop10-Lys(Dop10)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop11-Lys(Dop11)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop12-Lys(Dop12)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop13-Lys(Dop13)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop6-Lys(Dop6)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop7-Lys(Dop7)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop8-Lys(Dop8)-DPhe-cyclo [Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop9-Lys(Dop9)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop10-Lys(Dop10)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop11-Lys(Dop11)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop12-Lys(Dop12)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂, orDop13-Lys(Dop13)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 13. The chimeric analog ofclaim 1, wherein said chimeric analog comprises a compound according tothe formula of:Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂, orDop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 14. The chimeric analog ofclaim 1, wherein said chimeric analog comprises a compound according tothe formula of:Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂, orDop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 15. The chimeric analog ofclaim 14, wherein said chimeric analog comprises a compound according tothe formula of:Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2; or apharmaceutically acceptable salt thereof.
 16. The chimeric analog ofclaim 14, wherein said chimeric analog comprises a compound according tothe formula of: Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂;or a pharmaceutically acceptable salt thereof.
 17. The chimeric analogof claim 14, wherein said chimeric analog comprises a compound Accordingto the formula of: Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂;or a pharmaceutically acceptable salt thereof.
 18. The chimeric analogof claim 1, wherein said chimeric analog comprises a compound accordingto the formula of:Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], orDop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; ora pharmaceutically acceptable salt thereof.
 19. A compound useful as anintermediate in a chemical synthesis, wherein said intermediatecomprises a compound according to the formula of: (3), (6), (11), (14),(18), (21), (24), or (27);

or an organic or inorganic salt thereof.
 20. A method of eliciting adopamine receptor agonist effect in a subject in need thereof, whereinsaid method comprises administering to said subject an effective amountof a chimeric analogue of the invention, wherein said chimeric analoguecomprises a compound according to the formula of Formula (I), (II),(III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or apharmaceutically acceptable salt thereof; a compound according to claim12; or a pharmaceutically acceptable salt thereof; or intermediatecompound (3), (6), (11), (14), (18), (21), (24), or (27); or an organicor inorganic salt thereof; and wherein said effective amount is theamount effective to elicit a dopamine receptor agonist effect in saidsubject.
 21. The method of claim 20, wherein said chimeric analoguecomprises a compound according to the formula of:Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂, orDop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 22. The method of claim 21,wherein said chimeric analogue comprises a compound according to theformula of:Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂, orDop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 23. The method of claim 22,wherein said chimeric analogue comprises a compound according to theformula of:Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2; or apharmaceutically acceptable salt thereof.
 24. The method of claim 22,wherein said chimeric analogue comprises a compound according to theformula of: Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; ora pharmaceutically acceptable salt thereof.
 25. The method of claim 22,wherein said chimeric analogue comprises a compound according to theformula of: Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 26. The method of claim 20,wherein said chimeric analogue comprises a compound according to theformula of:Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], orDop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; ora pharmaceutically acceptable salt thereof.
 27. A method of eliciting asomatostatin receptor agonist effect in a subject in need thereof,wherein said method comprises administering to said subject an effectiveamount of a chimeric analogue of the invention, wherein said chimericanalogue comprises a compound according to the formula of: Formula (I),(II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or apharmaceutically acceptable salt thereof; a compound according to claim12; or a pharmaceutically acceptable salt thereof; or intermediatecompound (3), (6), (11), (14), (18), (21), (24), or (27); or an organicor inorganic salt thereof; and wherein said effective amount is theamount effective to elicit a dopamine receptor agonist effect in saidsubject.
 28. The method of claim 27, wherein said chimeric analoguecomprises a compound according to the formula of:Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo [Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂, orDop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 29. The method of claim 28,wherein said chimeric analogue comprises a compound according to theformula of:Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; orDop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂.or apharmaceutically acceptable salt thereof.
 30. The method of claim 29,wherein said chimeric analogue comprises a compound according to theformula of:Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2; apharmaceutically acceptable salt thereof.
 31. The method of claim 29,wherein said chimeric analogue comprises a compound according to theformula of: Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; ora pharmaceutically acceptable salt thereof.
 32. The method of claim 29,wherein said chimeric analogue comprises a compound according to theformula of: Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂.or apharmaceutically acceptable salt thereof.
 33. The method of claim 27,wherein said chimeric analogue comprises a compound according to theformula of:Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], orDop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; ora pharmaceutically acceptable salt thereof.
 34. A method of elicitingboth a dopamine receptor agonist effect and a somatostatin receptoragonist effect in a subject in need thereof, wherein said methodcomprises administering to said subject an effective amount of achimeric analogue of the invention, wherein said chimeric analoguecomprises a compound according to the formula of Formula (I), (II),(III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or apharmaceutically acceptable salt thereof; a compound according to claim12; or a pharmaceutically acceptable salt thereof; or intermediatecompound (3), (6), (11), (14), (18), (21), (24), or (27); or an organicor inorganic salt thereof; and wherein said effective amount is theamount effective to elicit both a dopamine receptor agonist effect and asomatostatin receptor agonist effect in said subject.
 35. The method ofclaim 34, wherein said chimeric analogue comprises a compound accordingto the formula of:Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂, orDop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 36. The method of claim 35,wherein said chimeric analogue comprises a compound according to theformula ofDop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; orDop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂.or apharmaceutically acceptable salt thereof.
 37. The method of claim 36,wherein said chimeric analogue comprises a compound according to theformula ofDop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2; apharmaceutically acceptable salt thereof.
 38. The method of claim 36,wherein said chimeric analogue comprises a compound according to theformula of Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 39. The method of claim 36,wherein said chimeric analogue comprises a compound according to theformula of Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂.or apharmaceutically acceptable salt thereof.
 40. The method of claim 34,wherein said chimeric analogue comprises a compound according to theformula of:Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], orDop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; ora pharmaceutically acceptable salt thereof.
 41. A pharmaceuticalcomposition comprising an effective amount of a compound according tothe formula of: Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII),(IX), or (X); or a pharmaceutically acceptable salt thereof; a compoundaccording to claim 12; or a pharmaceutically acceptable salt thereof; orintermediate compound (3), (6), (11), (14), (18), (21), (24), or (27);or an organic or inorganic salt thereof; in a pharmaceuticallyacceptable carrier, wherein said effective amount is the amounteffective to elicit a dopamine receptor agonist effect or a somatostatinreceptor agonist effect or both in a subject in need thereof.
 42. Thepharmaceutical composition of claim 41, wherein said chimeric analoguecomprises a compound according to the formula of:Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂, orDop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 43. The pharmaceuticalcomposition of claim 42, wherein said chimeric analogue comprises acompound according to the formula of:Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; orDop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂.or apharmaceutically acceptable salt thereof.
 44. The pharmaceuticalcomposition of claim 43, wherein said chimeric analogue comprises acompound according to the formula of:Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2; apharmaceutically acceptable salt thereof.
 45. The pharmaceuticalcomposition of claim 43, wherein said chimeric analogue comprises acompound according to the formula of:Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or apharmaceutically acceptable salt thereof.
 46. The pharmaceuticalcomposition of claim 43, wherein said chimeric analogue comprises acompound according to the formula of:Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂.or apharmaceutically acceptable salt thereof.
 47. The pharmaceuticalcomposition of claim 41, wherein said chimeric analogue comprises acompound according to the formula of:Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], orDop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; ora pharmaceutically acceptable salt thereof.
 48. A method of treating adisease or condition in a subject, said method comprising administeringto said subject a therapeutically effective amount of a chimeric analog,wherein said chimeric analog comprises a compound according to theformula of: Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII),(IX), or (X); or a pharmaceutically acceptable salt thereof; a compoundaccording to claim 12; or a pharmaceutically acceptable salt thereof; orDop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo [Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], orDop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; ora pharmaceutically acceptable salt thereof; or intermediate compound(3), (6), (11), (14), (18), (21), (24), or (27); or an organic orinorganic salt thereof; and wherein said disease or disorder is selectedfrom the list consisting of a neuroendocrine tumor; a vascular disease;a connective tissue disease; an immune disease; a disorder of thegastrointestinal tract, pancreas, kidney, or liver; a metabolic disease;a cachexia; cancer or a tumor of the lung, breast, prostate, liver,thyroid, blood; a musculoskeletal disorder; a panic disorder; opioidoverdose; portal hypertension; gastrointestinal bleeding; and whereinsaid therapeutically effective amount is the amount effective to treatsaid disease or disorder in said patient.
 49. The method of claim 48,wherein said neuroendocrine tumor is a neuroendocrine tumor of thepituitary.
 50. The method of claim 49, wherein said neuroendocrine tumorof the pituitary is an ACTH-producing tumor.
 51. The method of claim 50,wherein the condition of said ACTH-producing tumor is Cushing's disease.52. The method of claim 49, wherein said neuroendocrine tumor of thepituitary is a growth hormone producing tumor.
 53. The method of claim52, wherein the condition of said growth hormone producing tumor isacromegaly.
 54. The method of claim 49, wherein said neuroendocrinetumor of the pituitary is a prolactin-producing tumor.
 55. The method ofclaim 49, wherein the condition of said neuroendocrine tumor of thepituitary is a prolactinoma.
 56. The method of claim 54, wherein thecondition of said prolactin-producing tumor or prolactinoma ishyperprolactinemia.
 57. The method of claim 49, wherein saidneuroendocrine tumor of the pituitary is thyroid stimulating hormone(TSH) secreting tumor.
 58. The method of claim 49, wherein saidneuroendocrine tumor of the pituitary is “nonfunctioning” pituitaryadenoma.
 59. The method of claim 49, wherein said neuroendocrine tumorof the pituitary is gonadotropinoma.
 60. The method of claim 48, whereinthe neuroendocrine tumor is carcinoid tumor.
 61. The method of claim 60,wherein said carcinoid tumor causes carcinoid syndrome.
 62. The methodof claim 48, wherein said neuroendocrine tumor is glucagonoma.
 63. Themethod of claim 48, wherein said neuroendocrine tumor is small cell lungcarcinoma.
 64. The method of claim 48, wherein said neuroendocrine tumoris thyroid medullary carcinoma.
 65. The method of claim 48, wherein saidneuroendocrine tumor is VIPoma.
 66. The method of claim 48, wherein saidneuroendocrine tumor is insulinoma.
 67. The method of claim 48, whereinthe disorder of said vascular disease is inappropriate angiogenesis. 68.The method of claim 48, wherein the disorder of said vascular disease isrestenosis.
 69. The method of claim 48, wherein the disorder of saidvascular disease is retinopathy.
 70. The method of claim 69, whereinsaid retinopathy is diabetic retinopathy.
 71. The method of claim 69,wherein said retinopathy is proliferative retinopathy.
 72. The method ofclaim 69, wherein said retinopathy is macular degeneration.
 73. Themethod of claim 72, wherein said macular degeneration is age-relatedmacular degeneration.
 74. The method of claim 48, wherein saidconnective tissue disease is scleroderma.
 75. The method of claim 48,wherein said immune disease is rheumatoid arthritis.
 76. The method ofclaim 48, wherein said immune disease is inflammation.
 77. The method ofclaim 48, wherein said immune disease is fibrosis.
 78. The method ofclaim 48, wherein said immune disease is Graves' opthalmopathy.
 79. Themethod of claim 48, wherein said immune disease is allograft rejection.80. The method of claim 48, wherein said disorder of thegastrointestinal tract comprises gastric acid secretion, peptic ulcers,inflammatory bowel disease (IBD), or diarrhea.
 81. The method of claim80, wherein said IBD is irritable bowel syndrome or Crohn's disease. 82.The method of claim 48, wherein said metabolic disease compriseshyperlipidemia, insulin resistance, Syndrome X, obesity, diabetes, or adiabetes-related disease.
 83. The method of claim 82, wherein saiddiabetes-related disease comprises diabetic nephropathy, diabeticneuropathy, diabetic retinopathy, or gastroparesis.
 84. The method ofclaim 48, wherein said cachexia is cardiac cachexia, cancer cachexia, orgeriatric cachexia.
 85. The method of claim 58, wherein said chimericanalog comprises a SSTR-I agonist and a dopamine receptor agonist; or apharmaceutically acceptable salt thereof.
 86. The method of claim 85,wherein said chimeric analog further comprises a SSTR-2 agonist.
 87. Themethod of claim 85, wherein said chimeric analog further comprises aSSTR-3 agonist.
 88. The method of claim 86, wherein said chimeric analogfurther comprises a SSTR-3 agonist.
 89. The method of claim 85, whereinsaid chimeric analog further comprises a SSTR-5 agonist.
 90. The methodof claim 86, wherein said chimeric analog further comprises a SSTR-5agonist.
 91. The method of claim 87, wherein said chimeric analogfurther comprises a SSTR-5 agonist.
 92. The method of claim 88, whereinsaid chimeric analog further comprises a SSTR-5 agonist.
 93. The methodof claim 48, wherein said chimeric analog comprises a SSTR-2 agonist anda dopamine receptor agonist; or a pharmaceutically acceptable saltthereof.
 94. The method of claim 93, wherein said chimeric analogfurther comprises a SSTR-5 agonist.
 95. The method of claim 48, whereinsaid chimeric analog comprises a SSTR-3 agonist and a dopamine receptoragonist; or a pharmaceutically acceptable salt thereof.
 96. The methodof claim 48, wherein said chimeric analog comprises a SSTR-5 agonist anda dopamine receptor agonist; or a pharmaceutically acceptable saltthereof.
 97. A method of treating acromegaly in a subject in needthereof, wherein said method comprises administering to said subject atherapeutically effective amount of a chimeric analog, wherein saidchimeric analog comprises a compound according to the formula of:Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X);or a pharmaceutically acceptable salt thereof; a compound according toclaim 12; or a pharmaceutically acceptable salt thereof; orDop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], orDop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; ora pharmaceutically acceptable salt thereof; or intermediate compound(3), (6), (11), (14), (18), (21), (24), or (27); or an organic orinorganic salt thereof; and wherein said therapeutically effectiveamount is the amount effective to treat acromegaly in said patient. 98.The method of claim 97, wherein said chimeric analog comprises a SSTR-5agonist and a dopamine receptor agonist.
 99. The method of claim 98,wherein said chimeric analog further comprises a SSTR-2 agonist.
 100. Amethod of treating hyperprolactinemia in a subject in need thereof,wherein said method comprises administering to said subject atherapeutically effective amount of a chimeric analog, wherein saidchimeric analog comprises a compound according to the formula of:Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X);or a pharmaceutically acceptable salt thereof; a compound according toclaim 12; or a pharmaceutically acceptable salt thereof; orDop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo [Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], orDop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; ora pharmaceutically acceptable salt thereof; or intermediate compound(3), (6), (11), (14), (18), (21), (24), or (27); or an organic orinorganic salt thereof; and wherein said therapeutically effectiveamount is the amount effective to treat prolactinemia in said patient.101. The method of claim 100, wherein said chimeric analog comprises aSSTR-5 agonist and a dopamine receptor agonist.
 102. The method of claim101, wherein said chimeric analog further comprises a SSTR-2 agonist.